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Nadine N. Bewry 
 
ABSTRACT 
 
Imatinib mesylate (imatinib) represents a potent molecularly targeted 
therapy against the oncogenic tyrosine kinase, BCR-ABL. Although imatinib has 
shown considerable efficacy against chronic myeloid leukemia (CML), displaying 
high rates of complete hematological and complete cytogenetic responses, 
treatment with imatinib is not curative and overtime advanced-stage CML 
patients often become refractory to further treatment. Acquired resistance to 
imatinib has been associated with mutations within the kinase domain of BCR-
ABL, BCR-ABL gene amplification, leukemic stem cell quiescence as well as 
over-expression of the multidrug resistance (MDR1) gene. However, in vitro 
resistance models often fail to consider the role of the tumor microenvironment in 
the emergence of the imatinib-resistant phenotype. The bone marrow is the 
predominant microenvironment of CML and is a rich source of both soluble 
factors and extracellular matrixes, which may influence drug response. To 
address the influence of the bone marrow microenvironment on imatinib 
  xiv 
sensitivity, we utilized an in vitro co-culture bone marrow stroma model. Using a 
transwell system, we demonstrated that soluble factors secreted by the human 
bone marrow stroma cell line, HS-5, were sufficient to cause resistance to 
apoptosis induced by imatinib in CML cell lines. We subsequently determined 
that culturing CML cells in HS-5-derived conditioned media (CM) inhibits 
apoptosis induced by imatinib and other second generation BCR-ABL inhibitors. 
These data suggest that more potent BCR-ABL inhibitors will not overcome 
resistance associated with the bone marrow microenvironment. Additionally, we 
determined that CM increases the clonogenic survival of CML cells following 
treatment with imatinib. HS-5 cells are reported to express several cytokines and 
growth factors known to activate signal transducer and activator of transcription 3 
(STAT3). Given its crucial role in the survival of hematopoietic cells, we asked 
whether, 1) CM derived from HS-5 cells can activate STAT3 in CML cells and 2) 
does activation of STAT3 confer resistance to BCR-ABL inhibitors. We 
demonstrated that exposure of the CML cell lines, K562 and KU812, to CM 
caused an increase in phospho-Tyr STAT3, while no increases in phospho-Tyr 
STAT5 were noted. Moreover, resistance was associated with increased levels of 
the STAT3 target genes, Bcl-xl, Mcl-1 and survivin. Furthermore, reducing 
STAT3 levels with siRNA sensitized K562 cells cultured in CM to imatinib-
induced cell death (p<0.05, Student’s t-test). Importantly, STAT3 dependency 
was specific for cells grown in CM, as reducing STAT3 levels in regular growth 
conditions had no effect on imatinib sensitivity. Together, these data support a 
  xv 
novel mechanism of BCR-ABL-independent imatinib resistance and provide 
preclinical rationale for using STAT3 inhibitors to increase the efficacy of imatinib 
within the context of the bone marrow microenvironment. 
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CHAPTER I 
INTRODUCTION 
 
Hematopoiesis  
Although an estimated 1 x 1010 red blood cells and 1 x 109 white blood 
cells are produced per hour, mature blood cells have a limited lifespan of only a 
few hours to a few days and, therefore, require continuous production. 
Hematopoiesis is the highly regulated process of blood cell production from 
hematopoietic stem cells (HSCs) within the bone marrow (Figure 1). This 
process, which continues throughout adulthood, first begins in the embryonic yolk 
sack during the first weeks of embryonic development, proceeds in the liver and 
then the spleen. In adults, the bone marrow becomes the major site of 
hematopoiesis and ceases in the liver and spleen. The primary locations of HSC 
production are femurs, hip, ribs, sternum, as well as other bones.  
HSCs are small, non-adherent, rounded cells that possess a rounded 
nucleus and can be identified by their low cytoplasm-to-nucleus ratio. 
Characterized by their multipotency and high replicative and differentiation 
capacity, HSCs are capable of giving rise to all types of blood cells, which are 
divided into three distinct lineages: lymphoid, myeloid and erythroid. The 
lymphoid lineage of HSCs is composed predominantly of T-cells and B-cells, a 
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category of leukocytes or white blood cells (WBCs) called lymphocytes. Although 
they are the smallest WBCs, they are the cornerstones of the immune system, 
playing vital roles in the cell-mediated and humoral components of adaptive 
immunity, respectively. This lineage also consists of natural-killer (NK) cells, 
which plays a central role in defending the body from both tumors and virally 
infected cells. The myeloid lineage produces another category of leukocytes that 
include granulocytes, megakaryocytes and macrophages. Granulocytes, also 
known as polymorphonuclear leukocytes (PMN or PML) because of the varying 
shapes of the nucleus, consist of: 1) basophils, the least common of the 
granulocytes that play a role in regulating the immune inflammatory response to 
allergens and drugs; 2) eosinophils, which also respond to allergens and are 
involved in defending against infection and parasites; and 3) neutrophils, the 
most abundant WBCs in the body that contain granules of bacteria-killing 
enzymes in their cytoplasm and function as phagocytes, responding primarily to 
acute inflammation due to bacterial infection or fungi. Megakaryocytes produce 
blood platelets, which are small cells necessary for normal blood clotting. 
Macrophages are phagocytes involved in both innate and adaptive immunity. The 
third lineage of HSCs, the erythroid lineage, gives rise to oxygen-carrying red 
blood cells (RBC), which make up 45% of blood volume. 
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Figure 1. The Process of Hematopoiesis. All of the cellular components of the 
blood are derived from hematopoietic stem cells. Blood cells are divided into 
three lineages: lymphoid, myeloid and erythroid. 
Types of Leukemia 
Hematopoiesis is highly regulated by a balance of growth and death 
signals that determine the fate of each cell in the hematopoietic system. 
Consequently, mutations of stem cells can disrupt the hematopoietic system to 
confer a growth advantage. This deregulated hematopoiesis creates an 
imbalance between cell production, destruction and differentiation and can lead 
to a number of hematologic diseases. Leukemia, the abnormal proliferation of 
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blood cells in the bone marrow, results in deregulated blood cell production and 
cell differentiation.  
Leukemia is classified as acute or chronic based on pathological and 
clinical characteristics, such as the speed with which the disease progresses and 
the phenotype of the affected cells. While acute leukemia is distinguished by the 
rapid increase of WBCs, an increase in mature, yet abnormal blood cells typifies 
chronic leukemia. Leukemia can be further sub-divided as lymphoid or myeloid 
based on the lineage of the blood cells that are affected (Table 1). 
 
Normal vs. Leukemic Hematopoietic Stem Cells 
Normal HSCs are a rare, quiescent homogeneous cell population whose 
production is very tightly regulated. Additional characteristics of stem cells 
include their multipotent differentiation capacity and their ability to self-renew [1]. 
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Based on the latter characteristic, HSCs can be subdivided by their stem cell 
hierarchy, or the degree to which they are able to self-renew, as short- or long-
term repopulating cells [2]. 
Despite major advances in our understanding of stem cells, little is known 
about their role of stem cells in human malignancies. There is a growing body of 
evidence that lends support to the existence of cancer stem cells (CSCs), a 
small, primitive subpopulation of cancer cells that escape normal control and are 
capable of initiating, propagating and maintaining the cancer cell population [3]. 
Studies show that CSCs have been implicated in a number of human 
malignancies, including breast and brain tumors [4, 5]. 
Among the CSC subpopulation, studies have identified and characterized 
cancer-causing leukemic stem cells (LSCs).  These cells share many of the 
canonical properties of normal HSCs, such as multipotency, the ability to self-
renew, and extensive proliferative capacity [6, 7]. However, unlike normal HSCs, 
these LSCs display a reduced or absent exogenous growth factor-dependence 
[8]. Instead, these cancer-causing leukemic cells are capable of generating their 
own growth signals, most notably via the autocrine production of cytokines such 
as interleukein-3 (IL-3) and/or granulocyte colony-stimulating factor (GM-CSF) 
[9].  
Early studies using immunodeficient mice as xenotransplantation models 
demonstrated the existence of leukemia-initiating stem cells in CML patients [10-
13]. Like normal stem cells, these cells lack lineage markers (Lin-) and are 
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distinguished as follows: CD34+CD38- Thy-1+Lin- (Baum C, 1992), where CD34 
is a single-pass transmembrane glycoprotein that functions as a cell-cell 
adhesion factor and is expressed early in hematopoietic tissues [14]; CD38 is an 
early cell surface marker for white blood cells [15] and CD90 or Thy-1 is the 
thymocyte (T-cell precursor) marker [16]. Research done in these early CML 
models confirmed that while chronic phase CD34+ CML patient cells contained 
both normal and LSC fractions, patients in blast crisis phase CML have a greater 
preponderance of LSCs [17]. CML LSCs are not composed of a functionally 
homogeneous cell population as previously believed, but like normal HSCs, are 
comprised of a heterogeneous pool of short-term and long-term repopulating 
cells [18-20].  
Addressing the failures of cell cycle-active chemotherapeutic agents to 
eradicate CSCs in vivo and in vitro poses a challenge for CML patient care, as 
primitive quiescent cells are resistant to imatinib. This resistant, quiescent LSC 
phenotype coupled with an augmented stem cell population, an enhanced self-
renewal capacity and decreased growth-factor dependence/increased autocrine 
secretion of growth factors may contribute to chemo-resistance in CML patients 
and subsequent relapse.  
  7 
 
 
CHAPTER II 
CHRONIC MYELOID LEUKEMIA AND THE ‘PHILADELPHIA’ CHROMOSOME 
 
 Currently within the United States every 1 in 4 deaths is due to cancer 
[21]. Among cancers, chronic myeloid leukemia (CML) is possibly the most well-
studied. CML is a myeloproliferative disorder that is characterized by the 
neoplastic transformation and malignant expansion of pluripotent hematopoietic 
stem cells (HSCs) within the bone marrow resulting in cancer of the white blood 
cells. It accounts for 7% to 20% of all cases of leukemia, and according to the 
America Cancer Society estimates, in 2008 there will be 4,830 newly diagnosed 
cases of CML with 450 of those resulting in deaths. While it affects all age 
groups, it is predominantly affects middle-aged to elderly individuals at a rate of 
1-2 per 100,000. CML is the first disease to be linked to a clear, consistent 
genetic abnormality, the Philadelphia (Ph’) chromosome, which was first 
described in 1960 by Peter Nowell of the University of Pennsylvania and David 
Hungerford of the Fox Chase Cancer Center, two scientists from Philadelphia, 
Pennsylvania [22]. The team described a tiny acrocentric chromosome in cells 
cultured from the blood of seven patients harboring the disease. This 
chromosome later became the unique genetic signature and diagnostic clinical 
marker of CML patients [23]  
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The Ph’ chromosome is formed by the reciprocal translocation and fusion 
between the long arms of chromosomes 9 and 22 [t(9,22)(q34;q11)] [24-26] (see 
Figures 2A and B). Chromosome 9 encodes the proto-oncogene ABL, while 
chromosome 22 encodes the breakpoint cluster region gene (bcr), a 
serine/threonine kinase named after the site where it is located. This 
translocation event results in the formation of the chimeric oncogene, BCR-ABL, 
which gives rise to an aberrant and deregulated, constitutively active tyrosine 
kinase capable of activating numerous downstream targets.  
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Figure 2: The Philadelphia (Ph’) chromosome. CML is the first disease to be 
linked to a clear and consistent genetic abnormality, the Philadelphia 
chromosome. (A) Human karyotype, with chromosomes 9 and 22 highlighted; (B) 
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Formation of the Philadelphia chromosome. The Philadelphia chromosome is 
formed by the head-to-tail reciprocal translocation between the long arms of 
chromosome 9, which contains the proto-oncogenic ABL non-receptor tyrosine 
kinase, and chromosome 22, which contains the bcr serine/threonine kinase 
[t(9:22)(q34:11)]. 
CML is divided into three phases based on clinical characteristics that 
such as the amount of blast cells (immature, abnormal white blood cells) in the 
blood and bone marrow and the severity of symptoms presented (see Table 2). 
The initial chronic phase (CP), diagnosed in approximately 95% of patients, has 
an average duration of 4 to 6 years and is often asymptomatic, or patients may 
experience mild symptoms of fatigue, anemia, splenomelgaly, upper abdominal 
pain or mass. Less common presentations may include fever, weight loss, 
anorexia or gout. Chronic phase CML is characterized by an overproduction of 
immature myeloid and mature granulocytes in the spleen, peripheral blood and 
bone marrow; however, the cells retain the ability to differentiate and function 
normally. The lack of therapeutic intervention and the presence of additional 
genetic and/or epigenetic defects cause the disease to progress to an 
accelerated phase (AP), characterized by the presence of 10–20% primitive blast 
cells in the peripheral blood and bone marrow. When the disease advances to 
the ‘blast-crisis’ phase it resembles acute leukemias and is characterized by the 
presence of >20% undifferentiated blasts in the peripheral blood and bone 
marrow. At this grave stage patients have a life expectancy of 3-6 months. 
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While the cause of the initial translocation event which gives rise to CML 
remains unclear, studies have shown that translocation can be induced by 
ionizing radiation (IR) [27]. Additionally, the physical distance between the BCR 
gene and the ABL gene in human hematopoietic progenitor cells is shorter than 
might be expected by chance and could favor translocation between the two 
genes [28, 29].  
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The BCR-ABL Protein 
BCR-ABL’s oncogenic capacity is mediated by its multiple modular 
domains inherited from BCR and ABL that facilitate diverse protein-protein 
interactions (some of BCR-ABL’s protein targets are described in Table 3).  
  13 
Structure of c-BCR Protein 
The 160-kd (p160) breakpoint cluster region protein, BCR, is a large multi-
domain, ubiquitously expressed serine/threonine kinase comprised of 1,271 
amino acids (Figure 3). At its NH2-terminus, BCR has a coiled-coil/oligomeric 
domain which enables the protein to dimerize in vivo [30]. The serine/threonine 
kinase domain defines the protein’s function by phosphorylating substrate on 
either serine or threonine residues. Known substrates of BCR include Bap-1, a 
member of the 14-3-3 family of proteins [30, 31] and BCR itself [32]. Within the 
center of the protein is the Rho/guanine nucleotide exchange factor (Rho/GEF) 
domain that is specific for the Rho-subfamily of small GTPases, RhoA and 
CDC42. Both small GTPases regulate actin cytoskeleton rearrangement and 
control cell functions such as cell migration, morphology and cell cycle 
progression. The Rho/GEF domain also interacts with and activates transcription 
factors such as NF-kB [33]. This domain is followed by the Pleckstrin homology 
(PH)/Calcium-dependent lipid binding (CaLB) domain that binds phospholipids, 
such as phosphotidylinositides (PI). This interaction plays an important role in 
signal transduction by localizing the protein to cellular membranes and activating 
second messenger. The carboxyl-terminus of the protein contains a Rac-GTPase 
activating protein (Rac-GAP) domain [34], a small GTPase belonging to the Ras 
super-family that plays a role in regulating actin polymerization. Additionally, 
BCR’s tyrosine 177 (Y177) residue is an autophosphorylation site that is 
essential for binding to the adaptor molecule, GRB-2, and activating the mitogen 
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activated protein kinase (MAPK) signal transduction pathway. BCR-ABL 
autophosphorylation also occurs on Y283, Y328 and Y360 [35-37]. 
 
Figure 3: Structural Domains of The c-BCR Protein. There are several 
functional domains found within BCR: At its N-terminus lies an oligomerization 
domain; this is followed by a serine/threonine kinase domain; a Rho/Guanine 
nucleotide exchange factor (Rho/GEF) domain; a Pleckstrin homology (PH) 
domain and a Rac-GTPase activating protein (Rac-GAP) domain. Key residues 
include Y177 which enables mitogenic activation of the MAPK pathway via 
binding of the adaptor molecule GRB-2. 
Structure of c-ABL Protein 
 The c-ABL gene was initially identified as the human homologue of the 
Abelson murine leukemia virus (A-MuLV), which is the acute transforming 
retrovirus encoding the v-ABL oncogene [38]. It is located on chromosome 9q34, 
spans 230 kilobases (kb) and possesses 11 exons that encodes a 145 kilodalton 
(kD) (1,097 amino acids) non-receptor tyrosine kinase. In addition to c-ABL, the 
ABL family of non-receptor tyrosine kinases is also comprised of ARG (ABL-
related gene, designated ABL2).  
Like BCR, ABL is expressed ubiquitously within the cell, but predominates 
within the nucleus and cytoplasm. Its diverse localization within the cell reflects 
its diverse functions, which are mediated by its protein-protein interactions. 
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These interactions facilitates ABL’s involvement in numerous cellular processes, 
including cellular response to DNA damage and genotoxic stress [32, 39-41], cell 
cycle regulation [28, 42] and rearrangement and cell migration [43]. There are 
two isoforms, designated 1b and 1a, which are generated by alternative splicing 
of the first exon (Figure 4) and are driven by their own promoters. Differing only 
in their NH2-terminus sequences, the 1b isoform encodes a 6.5 kb mRNA, while 
the 1a isoform encodes a slightly shorter 5 kb transcript that is 19 amino acids 
shorter than 1b.  
Within the amino-terminus of the 1b isoform lies a myristoylation site 
which enables plasma membrane- attachment. This site is missing in the 1a 
isoform. Further within the NH2-terminus are three SRC-homology domains, 
SH1-SH3. The SH1 tyrosine kinase domain defines protein’s function. It contains 
two key residues: Y412, the site of phosphorylation in transformed cells, and 
Y393, the major site of autophosphorylation within the proto-oncogene’s kinase 
domain. Both the SH2 and SH3 domains are involved in mediating protein-
protein interactions: the SH2 domain binds to the phosphotyrosine regions of 
target proteins, while the SH3 domain recognizes proline residues. Within the 
center of the protein is a proline-rich region (P) which, conversely, binds the SH3 
domains of other protein substrates [44]. Towards the carboxyl-terminus there 
are three (NLS) [42, 45], a DNA binding domain (DNA BD) [45], a nuclear 
exporting signal (NES), and an actin-binding domain which mediates binding to 
globular/ monomeric (G) and filamentous (F) actin.  
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Figure 4: Structural Domains of The c-ABL Protein. There are several 
functional domains found within ABL: a myristoylation site; SRC-homology (SH) 
domains SH1-3; four proline-rich regions (P); three nuclear localization signal 
(NLS) regions; a DNA binding domain (DNA BD; an actin binding domain and a 
nuclear export signal (NES). 
One BCR-ABL Oncogene, 3 BCR-ABL Proteins Isoforms 
Breakpoints within the BCR gene results in primary fusion BCR-ABL 
transcripts with the same portion of ABL sequence in the carboxyl-terminus, but 
include different amounts of bcr sequence at the NH2-terminus (see Figure 5A). 
Unlike ABL, which has only one breakpoint within a region greater than 300 kb at 
its 5’ end, BCR’s breakpoints are localized within three ‘breakpoint cluster 
regions’ (bcr) resulting in three BCR-ABL fusion proteins varying in size from 190 
to 230 kD (Figure 5B). Each isoform is associated with a different type of 
leukemia. 
In 95% of CML patients and 1% Ph-positive acute lymphoblastic leukemia 
(ALL) patients, the breakpoint occurs within the major breakpoint cluster region of 
BCR (M-bcr), a 5.8 kb area stretching across exons b12-b16. These patients 
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possess the p210 BCR-ABL isoform, which is formed when either exon b12 or 
b13 of BCR fuses with exon a2 of ABL.  
Most ALL patients possess the breakpoint within the minor bcr region (m-
bcr), which spans a 54.5 kb area between exons b1 and b2. The resulting p190 
BCR-ABL fusion protein is characteristic of ALL.  
The p230 BCR-ABL isoform is seen in patients with chronic neutrophilic 
leukemia (CNL), a rare disease in which too many stem cells develop into 
neutrophils. CNL may stay the same or progress quickly into acute leukemia. The 
recently characterized mu-bcr (µ-bcr), is associated with this form of leukemia 
and is located downstream of exon b19.  
The research presented here is focused on the role of p210 BCR-ABL in 
CML pathogenesis. 
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Figure 5: 1 BCR-ABL Oncogene, 3 BCR-ABL Proteins Isoforms. Fusion 
transcripts contain the same portion of the ABL within the carboxyl-terminus but 
different amounts of BCR sequence at the amino-terminus depending on where 
the breakpoints occur within BCR. (A), Breakpoint locations within the ABL and 
BCR genes. 3 breakpoint cluster regions (bcr) are found within the BCR gene: 
the major bcr (M-bcr), the minor bcr (m-bcr), and the mu bcr (µ-bcr). Breakpoints 
within each of these regions give rise to a different form of leukemia. ABL has a 
>300 kb breakpoint region between exons a1 and a2. (B), Structure of the 
chimeric BCR-ABL transcripts. The p190 BCR-ABL isoform is found in Ph-
positive ALL, the p210 isoform is found in CML, and the p230 isoform is found in 
CNL (Clinical Cancer Research Vol. 8, 2177-2187, July 2002). 
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CHAPTER III 
BCR-ABL PATHOGENESIS 
 
The Role of Modular Domains 
Features of key domains and motifs contribute to p210 BCR-ABL-
mediated malignant transformation in CML patients (Figure 6A). The 
oligomerization domain of BCR performs several crucial roles: 1) it enables the 
chimeric BCR-ABL proteins to form dimers (or tetramers) and to trans-
autophosphorylate, which abrogates the need for regulatory external kinases 
(see Figure 6B); 2) it is an essential activator of ABL kinase activity [30]; and, 3) it 
promotes the association of BCR–ABL with F-actin which facilitates cytoskeletal 
rearrangement, cell spreading and cell migration [43]. The GRB-2 binding site at 
tyrosine 177 activates both the MAPK survival pathway [46, 47], and the 
phosphatidylinositol 3-kinase (PI3K) anti-apoptotic pathway [47].  
Purified ABL is kinase-active, therefore regulatory cis- and trans-acting 
elements are believed to be involved in its constitutive inhibition. Intermolecular 
interactions within the first three tandem domains of ABL facilitate their assembly 
into an auto-inhibitory structure that negatively regulates the protein. The SH3 
domain interacts with Pro1124 within the SH2-linker region and results in a 
‘clamp’ structure that confines the kinase in an inactive confirmation [44, 48]. 
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Furthermore, the myristoylation site binds to the tyrosine-kinase domain of ABL, 
operating as a ‘latch’ that reinforces the SH3–SH2 ‘clamp’ [48, 49]. Studies show 
that the SH3 domain is intrinsically capable of suppressing the transforming 
ability of ABL and its deletion or mutation fully activates the kinase [39]. 
Additionally, a number of proteins also bind to the SH3 domain of ABL and serve 
as negative regulators of the proto-oncoprotein. ABL interactor proteins 1 and 2 
(Abi-1 and Abi-2) bind to ABL’s SH3 domain and activate the inhibitory function 
of this domain [50-52]. Additionally Pag/Msp23, another ABL SH3-binding 
protein, dissociates from ABL under oxidative stress and facilitates its tyrosine 
kinase activity [53].  
Fusion of BCR with ABL breaks the intermolecular bonds within ABL’s SH 
domains and disrupts its constitutively inhibited regulatory configuration. 
Furthermore, activated ABL tyrosine kinase triggers the ubiquitin-proteasome-
mediated destruction of the Abi proteins that normally antagonize its oncogenic 
potential [54].  
Collectively, deregulation of BCR and ABL’s multiple domains is a major 
contributing factor in CML pathogenesis. 
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Figure 6: Structure of p210 BCR-ABL Protein. (A), BCR-derived sequences 
and ABL-derived sequences. Fusion of BCR to ABL is central to the 
pathogenesis of CML as it not only disrupts ABL’s regulatory configuration but 
also disrupts BCR-ABL’s localization within the cell. (B), Location of trans-
autophosphorylation sties within BCR-ABL. Proteins are able to dimerize via their 
oligomerization domains and trans-self-phosphorylate on both Y177, a key 
binding site for GRB-2, and Y1124 within the activation loop of ABL’s kinase 
domain. 
Activation of Multiple Signaling Pathways  
BCR-ABL activates numerous pathways commonly used in hematopoietic 
growth factor receptor signaling. These activated pathways contribute to CML 
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pathogenesis by causing 1) constitutive mitogenic activation, inhibition of 
apoptosis and decreased adhesion to bone marrow stroma extracellular matrices 
(Figure 7).  
 
Figure 7: Mechanisms of Malignant Cell Transformation by BCR-ABL. BCR-
ABL-mediated malignant transformation in CML pathogenesis occurs via three 
major mechanisms: constitutive mitogenic activation, inhibition of apoptosis and 
decreased adhesion to bone marrow stroma extracellular matrices. 
Constitutive Mitogenic Activation: The Ras/MEK Pathway 
The Ras/extracellular-signal-regulated kinase (ERK) (Ras/ERK) transmits 
extracellular signals into the nucleus and results in gene transcription [55-57]. 
The autophosphorylated Y177 residue within BCR-ABL’s first exon serves as a 
docking site for growth factor-binding protein 2 (GRB-2)’s SH2 domain and 
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facilitates signal transduction (Figure 8). GRB-2 forms a complex with the 
guanine nucleotide exchange factor, son of sevenless (SOS) protein, which 
stabilizes RAS in its active GTP-bound conformation and induces its activation. 
RAS activation can also be mediated by three other adaptor molecules and BCR-
ABL substrates, SH2-containing protein (Shc), Crk-like protein (Crkl) and 
phospho-protein p62DOK [58-60]. 
RAS activation initiates a cascade of signaling events involved in CML 
pathogenesis. Activated Raf-1 (MAP KKK) phosphorylates MEK1/2 (MAP KK) on 
both serine and threonine residues; MEK1/2 then phosphorylates and activates 
the extracellular-signal regulated kinases, ERK1/2 (MAPK), which results in the 
phosphorylation and activation of the transcription factor Elk1. Upon activation, 
Elk-1 translocates to the nucleus and binds the serum response factor (SRF) 
transcription factor. This ternary complex then binds the serum response element 
(SRE) of the immediate early genes and proto-oncogenes, c-Fos and c-Jun, to 
direct their transcriptional activation and regulation.  
Together, c-Fos and c-Jun DNA-binding proteins heterodimerize to form 
the AP-1 transcription factor which upregulates the transcription of genes 
involved in cell proliferation, cell differentiation and mediating growth-factor 
independence. These genes include the G1-cyclin dependent kinases (CDKs) 
[61]; CDK regulator, cyclin D1 [62]; c-Jun [63]; the anti-apoptotic protein Bcl-xL 
[64]; granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic 
cytokine [65]; the second messenger, cyclic adenosine monophosphate (cAMP) 
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[66]; and cAMP response element binding protein (CREB) [67]. The upregulation 
of these genes is characteristic of CML pathogenesis. 
 
 
Figure 8: BCR-ABL Activates the Ras/MEK Mitogenic Signal Transduction 
Pathway. Autophosphorylation of BCR-ABL on Y177 results in its interaction with 
the adaptor molecule, GRB-2. GRB-2 interacts with the guanine nucleotide-
exchange factor, SOS, which in turn mediates RAS activation. The adaptor 
molecules Shc and Crkl can also mediate RAS activation. RAS is coupled to the 
mitogen activated protein kinase (MAPK) pathway by the serine/threonine 
kinase, Raf. Raf in turn phosphorylates mitogen activated and extracellular-signal 
regulated kinase kinases 1 and 2 (MEK1/2). This lead to a phosphorylation and 
activation of and extracellular-signal regulated kinase kinases 1 and 2 (Erk1/2) 
and the subsequent activation of the transcription factor Elk.  
  25 
Inhibition of Apoptosis 
The PI3/AKT Pathway 
The lipid kinase phosphoinositide 3-kinase (PI3K) represents a family of 
cytosolic, intracellular signaling proteins whose deregulation is associated with 
malignant cell transformation [68]. Class I PI3Ks, which are commonly activated 
in CML, are heterodimeric molecules that are composed of a regulatory and a 
catalytic subunit and can be divided into two subclasses, class 1A and B. While 
class1A consists of an 85 kD regulatory subunit (p85) and a 110 kD catalytic 
subunit (p110), class1B consists of only a 110 kD catalytic subunit 
(p110γ/PI3Kγ). The class 1A PI3K pathway is activated either in one of two ways: 
1) the p85 regulatory subunit binding to an activated tyrosine residue on the 
activated interleukin (IL)-3 receptor, or 2) by the p110 subunit binding to activated 
Ras. Once activated, PI3K translocates to the cell plasma membrane where it 
phosphorylates the membrane phospholipid PI(4,5)P2 to produce PI(3,4,5)P3. 
This in turn activates phosphoinositide-dependent protein kinase 1 (PDK1) and 
facilitates its membrane localization where it phosphorylates and activates 
protein kinase B (AKT), PI3K primary downstream effector protein. 
Activation of PI3K/AKT survival pathway is essential to BCR-ABL-
mediated leukemogenesis [69] (Figure 9). BCR-ABL interacts indirectly with the 
p85 subunit of PI3K through the adaptor molecules GRB-2 and SHC to stimulate 
the constitutive activation of the p110 catalytic subunit [70]. This interaction is 
mediated by BCR-ABL’s recruitment of GRB-2-associated binding protein 
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(GAB2) through GRB-2. GAB2 then activates the p85 regulatory subunit of PI3K, 
leading to constitutive AKT activation, which can also be achieved by SHC’s 
binding to the SH2 domain within BCR-ABL’s carboxyl-terminus.  
Mutations to the p85 subunit of PI3K resulted in the inhibition of BCR-ABL-
dependent growth in hematopoietic CML cells, which highlights the role of PI3K 
in BCR-ABL-mediated pathogenesis [71]. Additionally, BCR-ABL upregulates the 
transcription of the p110γ subunit of PI3K in several CML cell lines.  
Constitutive activation of the PI3K/AKT pathway suppresses apoptosis in 
several ways. AKT phosphorylates the pro-apoptotic protein, Bad, which is 
scavenged by the cytosolic protein 14-3-3 and neutralized. This decreases 
apoptosis by preventing Bad from binding and inhibiting the anti-apoptotic protein 
Bcl-xL [72]. AKT promotes cell survival by phosphorylating and suppressing the 
activity of FKHRL1/FoxO3, a member of the 14-3-3 Fork-head family of 
transcription factors. Phosphorylation by AKT sequesters FoxO3 in the 
cytoplasm, preventing it from translocating to the nucleus where it activates 
genes necessary for cell death, such as Bad and Bim [73, 74]. AKT-induced 
phosphorylation of the “initiator” death caspase, caspase-9, also decreases 
apoptosis by inhibiting its proteolytic activities directly [75]. The ubiquitously 
expressed serine/threonine kinase glycogen synthase kinase-3 (GSK-3), another 
key downstream target of AKT, also induces apoptosis in tumor cells [76]. 
However, induction of apoptosis by GSK-3 is inhibited when it is phosphorylated 
by AKT. Lastly, AKT activates the nuclear factor-kB (NF-kB) transcription-factor, 
  27 
which is involved in the transcription of anti-apoptotic genes. Normally NF-kB is 
held in the cytoplasm in an inactive complex with its inhibitor, IkB. However, 
phosphorylation of NF-kB by AKT releases the transcription factor and enables it 
to perform its anti-apoptotic gene transcription [77].  
 
Figure 9: BCR-ABL Activates the PI3K/AKT Anti-Apoptotic Signal 
Transduction Pathway. By recruiting GRB-2-associated binding protein (GAB2) 
or the adaptor molecule Shc, BCR-ABL activates the PI3K/AKT pro-survival 
pathway; a process which can also be mediated by the signaling adaptor protein 
Crk. This interaction facilitates PI3K/AKT –mediated anti-apoptotic signaling in by 
phosphorylation and inhibition of: 1) the pro-apoptotic protein Bad, making it 
incapable of suppressing the activity of Bcl-xL; 2) FKHRL1/FoxO3 , making it 
incapable of translocating to the nucleus to activate pro-apoptotic proteins; 3) the 
cysteine protease, caspase-9; 4) the serine/threonine kinase glycogen synthase 
kinase-3 (GSK-3). 
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The JAK/STAT Pathway 
Signal transducer and activators of transcription (STATs) were originally 
characterized as latent cytoplasmic transcription factors. They are members of a 
family transcription factors that are involved in normal cellular response to 
cytokines, such as cell differentiation. There are seven STAT proteins: STAT1, 
STAT2, STAT3, STAT4, STAT5 (which consists of two closely related proteins, 
STAT5A and STAT5B) and STAT6. They have diverse biological roles and 
control critical cellular functions including cycle progression, cell proliferation, 
survival, differentiation, apoptosis and oncogenesis.  
STAT-mediated signal transduction occurs in several steps. Extracellular 
binding of cytokines to their cognate receptors, followed by receptor dimerization, 
leads to the engagement of associated Janus kinases (JAKs), a family of four 
cytoplasmic non-receptor tyrosine kinases (JAK1, JAK2, JAK3 and Tyk2), to the 
receptors’ cytoplasmic tail. JAKs then become activated by auto-phosphorylation, 
causing them to phosphorylate tyrosine residues within the receptor ‘s 
cytoplasmic tails. These receptor-associated phosphotyrosine residues serve as 
docking sites that recruit latent cytoplasmic STAT monomers through its SH2 
domain. Further tyrosine phosphorylation by JAKs leads to activation of STAT 
molecules, which in turn induces the formation of STAT homo- or heterodimers 
through interaction of the phosphotyrosine of one molecule with the SH2 domain 
of the other molecule. STATs can also be activated directly by growth factor 
receptors, such as epidermal growth factor receptor (EGFR), platelet derived 
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growth factor receptor (PDGFR) and GM-CSF receptor (or CD116), as well as by 
cytoplasmic kinases and oncoproteins, such as SRC and ABL. Activated STAT 
dimers are translocated into the nucleus via importin α/β as well as Ran-GDP. 
Once inside the nucleus activated STAT molecules bind a unique cytokine 
inducible sequence named GAS (γ-interferon activated sequences) within the 
promoter of target genes, thereby activating gene transcription. The activation of 
STATs is required for repopulation of the stem cell pool, as well as cell 
proliferation and differentiation in response to external stimuli.  
Several STATs, particularly STATs 1, 3 and 5, are constitutively activated 
in several types of cancers. Typically STAT1 is involved in cell growth arrest [78, 
79], in promoting apoptosis [80] and is implicated as a tumor suppressor [81]. 
STAT3 and STAT5 are involved in cellular transformation, cell cycle progression 
and preventing apoptosis [82-84].  
Aberrant activation of cytokine-mediated signal transduction pathways 
involving STATs are capable of conferring cytokine-independent growth to 
leukemia cells [85]. In CML, BCR-ABL can induce phosphorylation and activation 
of STAT5 via its SH2 and SH3 domains, hijacking normal cellular functions by 
circumventing the need for cytokine-mediated STAT5 activation. BCR-ABL 
kinase-dependent STAT5 activation in CML cells has been shown to be an 
essential component of CML’s pathogenesis [86, 87] (see Figure 10).  
Cells with constitutive STAT activation promote malignant cell proliferation 
by upregulating the gene expression cyclin D1, a cell cycle regulator that controls 
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cell cycle progression from G1 to S phase, and c-Myc, a key transcription factor 
that promotes cell cycle progression by inhibiting the expression of p21, a cyclin-
dependent kinase inhibitor [88, 89]. c-Myc is also capable of upregulating the 
expression cyclins. Additionally, constitutively activated STATs inhibits apoptosis 
by upregulating the expression of members of the Bcl-2 family of anti-apoptotic 
proteins Bcl-xL, Bcl-2 and Mcl-1 (see Table 4 for list of pro- and anti-apoptotic 
Bcl-2 family of proteins).  
The combined effects of 1) deregulated cell cycle progression and, 2) 
reduced apoptosis, results in uncontrolled cell proliferation and malignant cell 
transformation characteristic in CML pathogenesis.  
 
The BCL-2 Family of Proteins. The Bcl-2 (B-cell lymphoma-2) family of proteins 
governs mitochondrial outer membrane permeability (MOMP). They are 
categorized functionally by their ability to promote or inhibit cell death (pro- or 
anti-apoptotic) and structurally by their Bcl-2 homology (BH) domains. Each 
protein possesses at least one of four of the characteristic BH domains, named 
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BH1-4, and can therefore be subdivided further into those that have multidomain 
and those that have BH3-only domain. With the exception of Mcl-1 and BLF/A1, 
which have three conserved BH domains, the anti-apoptotic family of proteins 
possesses all four domains. Conversely, with the exception of Bax, Bak and Bok 
which are multidomain proteins, all the pro-apoptotic family of proteins are BH3-
only domain-containing proteins. TM, transmembrane. 
Decreased Adhesion to Bone Marrow Stroma and Extracellular Matrices 
During hematopoiesis, cell differentiation and proliferation is tightly 
regulated through specific interactions between HSCs and bone marrow stroma. 
Transformed CML progenitor cells escape normal negative regulatory signals 
and exhibit enhanced motility and perturbed adhesion properties. Rho GTP 
activating proteins (GTPases) are important regulators of cell motility, cell 
adhesion, actin assembly and cell migration [90]. They play important roles within 
the cell by transducing extracellular regulatory signals to effector molecules 
(reviewed in [91]. Rac GTPases, Rac 1-3, are members of the Rho GTPase 
family and cycle between GDP- and GTP-bound states. BCR-ABL activates 
RhoA and Rac1 GTPases via BCR’s Rho/GEF domain and ABL’s Rac GAP 
domain respectively. Additionally, Rac1 and Rac2 are significantly upregulated in 
CD34+ chronic phase CML cells [92].  
BCR-ABL recruits and activates Rac1 through its interaction with its 
hematopoietic-specific GEF, Vav, which leads to alternations in actin assembly. 
Deregulation of actin assembly enhances the motility of CML cells and facilitates 
their diminished adhesion to bone marrow stroma [93]. CML cells also display 
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increased expression of focal adhesion proteins, such as focal adhesion kinase 
(FAK), talin and paxillin, when compared to normal cells. These focal adhesion 
proteins play important roles in cell motility and survival, and their increased 
expression enable CML cells to escape the normal negative regulatory signals 
provided by component of the BME [94]. Additionally, CML cells express an 
adhesion-inhibitory variant of β1 integrin that is not found in normal progenitor 
cells [95].  
Taken together, BCR-ABL-mediated cytoskeletal rearrangement 
contributes to CML pathogenesis. 
 
Figure 10: Summary of Signal Transduction Pathways Activated in BCR-
ABL-Mediated Leukemogenesis. BCR-ABL is capable of phosphorylating 
numerous substrates to activate signal transduction pathways shared by cytokine 
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receptors and are involved in the growth and differentiation of hematopoietic 
cells. These activated signal transduction pathways include: Ras/MEK, which 
results in promitotic transcriptional gene regulation; PI3/AKT; which results in 
suppression of apoptosis; JAK/STAT5, which results in pro-survival gene 
transcription; Rac-GTPase activation, which results in cytoskeletal reorganization 
and anchorage-independent growth. 
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CHAPTER IV 
TREATMENT FOR CHRONIC MYLOID LEUKEMIA 
 
Before Signal Transduction Inhibitors 
Prior to the development of targeted therapy against CML, therapeutic 
options included cytotoxic drugs such as busufan, hydroxyurea, recombinant 
interferon α (rIFNα), bone marrow transplant (BMT) and allogeneic stem cell 
transplantation (allo-SCT).  
Busulfan 
Busulfan is an inexpensive, oral alkylating agent that produces DNA-
crosslinks resulting in the inhibition of DNA and protein synthesis. It produces 
periods of hematologic response in patients and is often restricted to those who 
are intolerant or resistant to hydroxyurea (see Table 5 for a list of definitions of 
the types of response to CML treatment). While it lowers white blood cell (WBC) 
count, its myelosuppressive effects were often delayed and persistent, which 
complicated therapy. Additional draw-backs to using busulfan include 
hyperpigmentation and interstitial lung disease [96, 97].  
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Hydroxyurea 
Hydroxyurea is also a DNA-synthesis inhibitor that achieved hematologic 
remission in patients within 1-2 months of use and is normally well tolerated in 
CML patients. Although it has been shown to be better than busulfan, both drugs 
rarely induced cytogenic responses. Neither busulfan nor hydroxyurea prevented 
disease progression from chronic phase to acute phase in CML patients.  
Recombinant Interferon-Alpha 
 Recombinant interferon-alpha (IFNα) treatment produces cytogenetic 
response in 70% of patients, with 20% of those patients experiencing complete 
cytogenic response. Studies show that rIFNα works well against CML alone or in 
combination with cytarabine, another DNA-damaging agent. It increased patients’ 
survival rates and is the treatment of choice for patients who do not have a HLA-
matched bone marrow donor or are too old for BMT [98, 99]. Under rIFNα 
treatment patient survival at 5 years was 57%, compared to 42% in the other 
previously discussed treatment groups (CML Trailists’ Coorperative Group, J Nat 
Cancer Inst. 1997; 89:1616-1620). Unfortunately, rIFNa treatment is limited by its 
toxicity profile, with 15-25% of patients discontinuing treatment due to intolerable 
side effects and another 35-50% requiring dose reduction due to poor drug 
tolerance. Side effects include anorexia, fever, chills and postnasal drip.  
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Allogeneic Stem Cell Transplantation 
At present, only allogeneic stem cell transplantation (allo-SCT) is an 
effective and curative treatment option for CML patients, providing long-term 
disease eradication [100]. Stem cells are derived from the bone marrow or 
peripheral blood of donors. Results are best for patients in chronic phase when 
compared to those in accelerated or blast crisis phase. The long term survival 
rate using this treatment method is 50-60% for CML chronic phase patients, 15-
20 for accelerated phase patients, and <10% for blast crisis phase patients [101]. 
Treatment-related morbidity and mortality rates in allo-SCT patients are 
high and often associated with organ toxicity, complications from infection and 
chronic graft-versus-host disease (GVHD) [102]. Due to the difficulty in finding a 
healthy, young HLA-matched sibling or donor, allo-SCT is often reserved for 
patients under the age of 55 years old who are unresponsive to secondary BCR-
ABL inhibitors.  
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Rationally Designed BCR-ABL Signal Transduction Inhibitors 
Imatinib Mesylate 
Constitutive BCR-ABL kinase activity in HSCs is an essential component 
of CML pathogenesis. The identification of BCR-ABL as the hallmark oncogenic 
transforming protein in CML made it an ideal target for drug development. This 
gave rise to rationally designed, small bioavailable signal transduction inhibitors 
(STI) specific for the tyrosine kinase domain of BCR-ABL. Imatinib mesylate 
(imatinib, also known as Gleevec; formerly STI571 and CGP 57158; Novartis 
Pharmaceuticals Corporation, Basel, Switzerland) was identified as a lead 
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compound in a high throughput in vitro screening for tyrosine kinase inhibitors 
(TKIs). The 2-phenylaminopyrimidine-derivative was designed to bind the ATP 
binding site of ABL kinases (see Figure 11) While imatinib is also capable of 
binding to other kinases, such as the stem cell factor (SCF) cytokine receptor, c-
kit, and platelet-derived growth factor receptor (PDGFR), it is specific for ABL 
oncoproteins, including c-ABL and ETV1-ABL. 
Functionally, imatinib easily transverses the cell membrane and selectively 
binds the tyrosine kinase domain of BCR-ABL. This domain consists of a bi-lobed 
structure in which Mg-ATP is located in a deep cleft between the amino- and 
carboxyl-terminal lobes. BCR-ABL cycles between two distinct active and 
inactive states, acting as a “molecular switch” depending on the conformation of 
its activation loop which contains the highly conserved asparagine-
phenylalanine-glycine (DFG) motif.  
In an active kinase conformation, Y1294 in the activation loop becomes 
phosphorylated and takes on a ‘DFG-out’ configuration, in which these 
conserved residues are flipped out of their usual position. This open 
conformation provides a platform for substrate binding and activation.  
However, in the inactive kinase conformation, this DFG motif is folded into 
the ATP-binding site and makes a channel opening outside the threonine 315 
gatekeeper residue [103]. This residue is essential as it is located near the ABL 
catalytic domain in the middle of the imatinib binding site and controls access to 
the hydrophobic region of the enzymatic active site. The inactive conformation of 
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BCR-ABL causes an auxiliary binding site within the ATP-binding pocket to open, 
which facilitates imatinib binding by the formation of hydrogen bonds. Interaction 
with imatinib traps and stabilizes BCR-ABL tyrosine kinase in an inactive, 
“closed” conformation, which terminates its kinase activity and inhibits its auto- 
and substrate phosphorylation [104].  
With has an IC50 value of 0.5 µM, imatinib has been shown to induce 
apoptosis in BCR-ABL+ cell lines as well as in primary leukemia cells from CML 
patients [105] (see Table 6 for a profile of BCR-ABL inhibitors). Cells undergo 
apoptosis within 48 to 72 hours following imatinib treatment. 
Chronic phase CML patients who had failed rIFNα-therapy and were 
treated with 400 mg/day of imatinib did not progress to accelerated or blast crisis 
phase. Additionally, 95% of achieved complete hematologic response and 60% 
had a major cytogenic response (MCR). A long-term follow-up of these patients 
showed a 13% increase in the MCR rate to 73%, with 63% of patients having a 
CCR. Studies done in accelerated-phase CML patients were encouraging, 
though less dramatic. Eighty two percent of these patients showed hematologic 
responses, with MCR seen at 24% and CCR at 17%.  
Imatinib’s efficacy has revolutionized CML patient care ([104, 106]. By 
obstructing BCR-ABL’s tyrosine kinase domain and its ability to commandeer 
signal transduction pathways crucial for CML pathogenesis, imatinib inhibits 
BCR-ABL’s role in cell transformation at micromolar concentrations. 
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Yet despite the efficacy of imatinib, CML patients in advanced stages of 
the disease (whose in accelerated or blast crisis phase) eventually display 
inadequate responses to treatment and often experience relapse within a year 
[107].  
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Figure 11: Mechanism of Imatinib Action in Chronic Myeloid Leukemia 
Cells. (A), CML pathogenesis is mediated by the constitutive activation of the 
BCR-ABL oncoprotein, which binds ATP to phosphorylate and activate numerous 
substrates involved signal transduction and malignant cell transformation. (B), 
Chemical formula of imatinib (STI-571). (C), Imatinib works as a competitive 
inhibitor and ATP-mimic that selectively competes for and binds to the ATP 
binding site/tyrosine kinase (TK) domain of BCR-ABL. (D), Ribbon representation 
of the three dimensional crystal structure of the catalytic domain of the ABL 
tyrosine kinase in complex with imatinib (figure taken from Wikimedia Commons). 
Imatinib Resistant Chronic Myeloid Leukemia 
In vitro resistance models have played a critical role in identifying various 
mechanisms of primary (acquired) resistance that thwart the effects of imatinib 
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treatment. Patient relapse is associated to three main mechanisms of imatinib 
resistance: 1) point mutations within BCR-ABL’s tyrosine kinase domain that (a) 
directly interfere with the ability of imatinib to bind to BCR-ABL kinase domain, or 
(b) impair the ability of BCR-ABL to achieve the inactive conformation required 
for imatinib binding [108-111]; 2) bcr-ABL gene amplification, and 3) 
overexpression of drug transporters. 
Point Mutations within the BCR-ABL Kinase Domain 
Gorre et al. was the first to demonstrate the relationship between a point 
mutation at ABL kinase domain and imatinib resistance [108]. The most resistant 
kinase mutation occurs when threonine 315 gatekeeper residue changes to 
isoleucine (T315I). This change directly blocks the ability of imatinib to bind the 
kinase domain while still retaining BCR-ABL’s capacity to bind ATP and catalyze 
substrate phosphorylation. The T315I point mutation causes a shift in the 
equilibrium between BCR-ABL’s inactive and active states, restoring BCR-ABL 
kinase activity. This can be attributed to T315I-mutation-specific changes in 
phosphorylation pattern within the kinase domain. This mutation results in a shift 
in the phosphorylation of two key tyrosine residues within the ATP binding loop 
that confers an oncogenic fitness advantage to cells possessing this mutation 
[112].  
Imatinib mesylate resistance is commonly associated with mutations that 
alter the flexibility of the BCR-ABL kinase domain to adopt the inactive 
conformation needed for imatinib binding. A summary of some of these well-
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characterized mutations is provided in Table 7. Like T315I, these mutations result 
from amino acid substitutions and consist of approximately 25 amino acids 
residues distributed throughout the ABL kinase domain that provide varying 
degrees of imatinib resistance. In some patients with stable chronic phase CML a 
number of these mutations are associated with disease progression to advanced 
stages [113]. The most commonly characterized mutations that account for 60–
70% of all kinase mutations affect residues Gly250, Tyr253, Glu255, Met351 and 
Phe359.  
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BCR-ABL Gene Amplification 
Gene amplification of target proteins is often characteristic of malignant 
cell transformation and is a frequently used mechanism to generate drug 
resistant neoplastic cells. Studies show that resistance to imatinib also occurs 
through BCR-ABL gene amplification. Imatinib-resistant CML cells have 
displayed higher levels of BCR-ABL protein expression and phosphorylation 
when compared to parental, imatinib-sensitive cells due to robust overexpression 
of BCR-ABL mRNA transcripts [114]. Studies also show BCR-ABL gene 
amplification linked to the presence of additional copies of the gene in some CML 
patients [115]. In other patients, unusual karyotyping using banding cytogenetics 
coupled with the overexpression of BCR-ABL led to the discovery of multiple 
double minutes , which are small fragments of extrachromosomal DNA encoding 
the BCR-ABL gene [116] (Figure 12).  
Disease progression from chronic to accelerated or blast crisis phase in 
CML patients is associated with an increase in BCR-ABL transcripts during 
imatinib treatment [108, 117]. This increase in transcripts correlates with 
enhanced CML cell survival determined by their ability to overcome the apoptotic 
effects of imatinib. These results underscore the fact that BCR-ABL gene 
amplification is an important mechanism of acquired resistance to imatinib. 
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Figure 12: Gene Amplification Due to the Presence of Double Minutes. FISH 
showing cells in metaphase. Chromosomes stained in red and double minutes 
stained in green (left) and all nuclear DNA stained black (right). In both panels, 
the double minutes are indicated by arrow. Image taken from Wikipedia. This 
work is in the public domain in the United States because it is a work of the 
United States Federal Government. 
Overexpression of Drug Transporters 
Cancer cells exposed to chemotherapeutic agents for an extended period 
of time often develop a multidrug resistance (MDR) phenotype that is 
characterized by overexpression of the multidrug resistance1(MDR1; also called 
P-glycoprotein (P-gy), ABCB1 and CD243) efflux pump. The broad substrate 
specificity of MDR1 enables it to regulate the distribution and bioavailability of 
numerous drugs. In CML patients this results in an excessive efflux of imatinib, 
rendering the chemotherapeutic agent ineffective.  
The importance of MDR1 in imatinib resistance is reflected in one recent 
study that demonstrated that polymorphisms of the MDR1 gene are indicative of 
the type of molecular response CML patients may have to imatinib treatment 
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[118]. MDR1. Retroviral-mediated transfection of BCR-ABL+ cells with the MDR1 
gene greatly decreased its sensitivity to the apoptotic effects of imatinib, a 
phenotype that was could be reversed with the addition of MDR1 pump 
modulators [119]. Additionally, cell lines resistant to imatinib were capable of 
growing continuously in its presence due to increased expression of the MDR1 
gene. Furthermore, Dulucq et. al. also revealed that the presence of MDR-1 
polymorphisms correlated to suboptimal patient response to imatinib treatment 
[118]. Similarly, patients with CML and treated with high dose imatinib displayed 
drug clearance and drug resistance in a manner consistent with MDR1-mediated 
elimination [120].  
Nilotinib 
The need to address imatinib-resistant CML ushered in an active area of 
research focused on the development of second generation inhibitors. The 
observation that imatinib-resistance is predominantly associated with mutations 
within BCR-ABL kinase domain led to the development of other small-molecule 
ABL kinase inhibitors with less stringent binding requirements and that are more 
effective in combating resistance.  
One such inhibitor is nilotinib (AMN107, Novartis Pharmaceuticals 
Corporation, Basel, Switzerland) (AMN107; Novartis), another 
phenylaminopyrimidine derivative that followed a rational drug design based on 
the crystal structures of imatinib in complexes with ABL. It was developed by 
modifying the N-methylpiperazine ring within the imatinib molecule. This 
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modification facilitates greater hydrogen-bond interactions with wild-type and 
many imatinib-resistant kinase mutants by providing a better topological fit to the 
kinase domain. Clinical studies show that nilotinib is active against 32 of the 33 
mutant forms of BCR-ABL [121, 122]. It is approximately 30-fold more potent 
than imatinib as an ABL inhibitor, with an IC50 value of 30 nM. However, like 
imatinib, it possesses no significant activity against the T315I mutant protein.  
Nilotinib is effective in patients who are unresponsive to treatment with 
imatinib. When CML patients in accelerated-phase were treated with nilotinib 
they experienced a hematologic response rate of 47% and a MCR rate of 29%, 
with a 12-month survival rate of 79% [123]. Clinical studies show that nilotinib is 
also well-tolerated at doses of up to 600 mg daily [124]. 
Dasatinib 
The need to address imatinib-resistant CML also resulted in the 
development of dasatinib (BMS-354825; Bristol-Myers Squibb), a dual BCR-
ABL/SRC family kinase inhibitor (SFK: Fyn, Yes, SRC, Lyn, Lck, Fgr, Blk, Hck). It 
also has additional activity against c-Kit and PDGFR. Dasatinib is clinically more 
active than imatinib and nilotinib against both wild-type and mutant BCR-ABL 
proteins responsible for drug resistance [121, 125].  
Dasatinib has less stringent conformational requirements for interaction 
with BCR-ABL kinase domain than nilotinib. Consequently, it binds both the 
active and inactive conformations. Dasatinib induces complete hematologic 
remissions and major cytogenetic responses in imatinib-resistant CML patients in 
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all three phases, chronic, accelerated, and blast phases. Response rates show 
that 95% of patients with chronic-phase CML and 82% of patients in accelerated-
phase CML respond to dasatinib treatment during a >12 months median follow-
up timeframe [126]. However, like imatinib and nilotinib, dasatinib has no effect 
against the T315I mutation and nearly all blast crisis phase patients experience 
relapse in less than a year of treatment  
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CHAPTER V 
MINIMAL RESIDUAL DISEASE CHRONIC MYELOID LEUKEMIA 
 
Despite the efficacy of imatinib, nilotinib and dasatinib in achieving high 
rates of cytogenetic and hematological responses to varying degrees, they are 
unable to override all forms of drug-resistant kinase mutations. Overtime some 
CML patients, particularly those in advanced stages of the disease, become 
refractory to further treatment. In almost all patients the BCR-ABL transcript 
persists below the level of cytogenetic detection while undergoing treatment, 
indicating the presence of minimal residual disease (MRD) CML. This suggests 
that treatment with imatinib and more potent BCR-ABL inhibitors is not sufficient 
to eradicate this disease.  
Several factors have been implicated in contributing to MDR CML: 1) the 
failure to kill leukemic stem cells, 2) BCR-ABL gene amplification, 3) the 
presence of pre-existing BCR-ABL kinase mutations, 4) epigenetic changes, and 
5) the tumor microenvironment. 
Failure to Kill Leukemic Stem Cells 
The identification of a rare population of primitive quiescent BCR-ABL+ 
cells with an intrinsic insensitivity to imatinib treatment lends support this model 
[127-129]. In vitro studies of quiescent CD34+ leukemic cells revealed that they 
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were resilient against high-dose imatinib treatment of up to 10-folds higher than 
the normal dosage. Additionally, while imatinib suppressed the proliferation of 
leukemic colony-forming cells (CFCs) and long-term culture-initiating cells (LTC-
ICs) it did not induce apoptosis in these primitive cells.  
Furthermore, residual BCR-ABL+ stem cells persisted in the bone marrow 
of CML patients who had achieved CCR with imatinib. This indicates that 
primitive BCR-ABL+ CML cells that are capable of entering the cell cycle could 
repopulate the bone marrow compartment to facilitate patient relapse when 
imatinib is withdrawn.  
The insensitivity of leukemic stem cells to the apoptotic effects of imatinib, 
coupled with their self-renewing capacity are important contributing factors to 
MRD CML.  
Pre-existing Mutations within the BCR-ABL Tyrosine Kinase Domain 
In one study 12% of CML patients who had no cytogenetic response to 
imatinib therapy and who did not display bcr-ABL gene amplification possessed 
rare cells that had point mutations within the kinase domain at the time of 
diagnosis. This included the highly resistant Thr315Ile mutation [130]. 
Additionally, BCR-ABL+ imatinib-naive cells from CML patients possessed the 
Glu255Lys point mutation, which is involved in preventing the BCR-ABL kinase 
from adopting the inactive conformation needed for imatinib interaction [131]. 
Pre-existing mutations in BCR-ABL+ cells could facilitate their outgrowth 
during therapy owing to the selective pressure of imatinib. The ‘fitness’ 
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advantage conferred to these mutated cells would enable a clonal selection of 
the minor population of cells carrying the mutation.  
Epigenetic Contributions  
While the t(9;22) translocation that produces the BCR-ABL oncogenic 
tyrosine kinase is the major transforming even in CML, additional molecular 
and/or epigenetic changes have been implicated in CML oncogenesis. These 
changes are also associated with the transition from chronic to blast crisis phase 
that accompanies the emergence of MRD CML and patient relapse. 
Disease progression in CML patients has been linked to increase de novo 
DNA-methylation of the ABL promoter contained within a CpG island, which is 
associated with ABL gene silencing [132, 133]. This suggests that the course of 
the disease may be documented by the extent of CpG methylation.  
During chronic phase CML the expanded granulocytic lineage still retains 
its ability to differentiate. However, the accelerated and blast crisis phases are 
characterized by decreased cell differentiation and the subsequent accumulation 
of immature hematopoietic cells. Molecular changes resulting in differentiation 
arrest are associated with this transition. Gain-of-function mutations in GATA-2, a 
gene that serves as a negative regulator of hematopoietic stem progenitor cell 
differentiation, resulted in its enhanced transactivation capacity and augmented 
inhibition of hematopoietic cell differentiation [134].  
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Tumor Microenvironment 
The bone marrow microenvironment (BME) provides CML cells direct 
interaction with stromal cells and extracellular matrices (ECM), which may 
modulate drug response. We reported previously that adhesion to fibronectin was 
sufficient to protect K562 CML cells from imatinib-induced cell death (Damiano 
[135, 136]. Similar studies reveal that direct contact of leukemic cells with the 
human stromal cell line, HS-5, significantly increased cell proliferation, viability 
and colony formation [137]. Additionally, leukemic-stromal cell interactions 
enhanced in vitro leukemic cell survival while attenuating chemotherapy-induced 
cell killing. Using a co-culture model consisting of leukemic cells and bone 
marrow-derived stromal cells, studies show that this interaction resulted in 
increased activation of the several signal transduction pathways involved in cell 
survival, including PI3K/AKT, Ras/ERK and STAT3 [138]. 
The BME is also a rich source of cytokines and growth factors that could 
also influence drug response. While the retroviral transduction of BCR-ABL into 
severe combined immunodeficient (SCID) bone marrow progenitor cells grown 
healthy mice resulted in rapid, fatal, imatinib-resistant leukemia, its transduction 
into similar cells lacking the cytokine receptor common γ-chain resulted in 
imatinib-sensitivity. This suggests that cytokines within the microenvironment are 
responsible for conferring imatinib resistance [139]. Studies to identify cytokines 
involved in modulating imatinib sensitivity revealed that autocrine secretion of 
GM-CSF was involved. Its secretion activates the JAK/STAT5 pathway and 
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protects imatinib-naive and CML progenitor cells from death induce by BCR-ABL 
inhibitors [140]. Additionally, mutated CML cells were able to spread resistance 
to non-mutated cells through overexpression of IL-3, which resulted in the 
activation of the Ras/MEK and JAK2/STAT5 signal transduction pathways [141]. 
This highlights the importance of the bone marrow microenvironment in 
modulating imatinib response. This resistance can be conferred by either direct 
adhesion to bone marrow stroma or by the secretion of bone-marrow derived 
soluble factors. 
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CHAPTER VI 
THE ROLE SIGNAL TRANSDUCERS AND ACTIVATORS OF 
TRANSCRIPTION (STATS) IN CHRONIC MYELOID LEUKEMIA 
ONCOGENESIS AND DRUG RESISTANCE 
 
Receptor engagement by hematopoietic cytokines results in their 
phosphorylation and the activation of JAKs. These receptors consist of a unique 
ligand-binding subunit and a signal transducing subunit [142] (see Figure 13 for 
cytokine receptor families). STATs are activated transiently by numerous 
cytokines via JAKs [143], as well as SFKs [144].  
Various types of hematologic malignancies are associated with the 
aberrant, constitutive, cytokine-mediated activation of STAT proteins. In CML, 
BCR-ABL activates signal transduction pathways shared by many hematopoietic 
cytokines, including the STAT3 and STAT5 signaling pathways. 
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Figure 13: Cytokine-Receptor Families. Cytokine-receptors consist of a ligand-
binding subunit and a signal-transducing subunit. Hematopoietic cytokine 
receptors can be categorized based on their signaling subunit as follows: 1) 
those that signal through a single subunit, which includes growth hormone (GH), 
prolactin (PRL), erythropoietin (EPO); granulocyte colony-stimulating factor (G-
CSF), and thrombopoietin )THPO); 2) those that signal through the gp130 or gp 
130-related subunit, which includes interleukins (IL)-6, 11 and 12, leukemia 
inhibitory factor (LIF), oncostatin M, ciliary neurotrophic factor (CTNF), and 
cardiotropin-1 (CT-1); 3). those that signal through the gp140β-subunit or a 
ligand-binding α subunit, which includes IL-3 and 5, and granulocyte-macrophage 
colony-stimulating factor (GM-CSF); 4) those that signal through a common γ-
chain (γC) and a α or β ligand-binding subunits, which includes IL-2,4,7,9, and 15; 
5) those that signal through two more subunits, such as the interferon-γ (IFN-γ) 
subfamily of receptors, which includes IFNRI and II. 
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The Role of STAT3  
STAT3 governs signal transduction in growth factor-mediated control of 
hematopoiesis and myeloid cell differentiation. Its activation up-regulates the 
expression of genes associated with cell survival and proliferation including Bcl-x, 
Mcl-1, and cyclin D1 [89, 145, 146]. Persistent STAT3 activation has been 
detected in a variety of hematopoietic malignancies and solid tumors [147-149]. 
The enforced expression of BCR-ABL in primitive embryonic stem cells (ESCs) 
resulted in their persistent STAT3 activation and caused the cells to retain their 
primitive morphology by inhibiting their differentiation [150]. The increased 
activation of STAT3 in primary leukemia blast cells lends support to its 
involvement in disease progression of CML patients and their’ transition from 
chronic phase to blast crisis phase [151].  
Taken together, these observations highlight the role of amplified STAT3 
activation in the pathogenesis of CML and underscore its involvement in imatinib 
resistance. 
The Role of STAT5  
 STAT5 has gained prominence because it is often constitutively activated 
in a wide variety of human cancers, ranging from solid tumors seen prostate, 
lung, breast and colon cancers, to hematologic malignancies, such as 
myeloproliferative disorders [152-155]. It is activated by non-receptor tyrosine 
kinases, such as BCR-ABL and SFKs. Like STAT3, STAT5 activation up-
regulates the expression of Bcl-x, Mcl-1, and cyclin D1. 
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BCR-ABL-dependent STAT5 activation was observed in several leukemic 
cell lines possessing the Ph+ clone, but not untransformed cells or BCR-ABL-
negative leukemia cells [154, 156]. Furthermore, the expression of BCR-ABL in 
IL-3/GM-CSF-dependent leukemic cells resulted in aberrant STAT5 activation 
and growth factor independence [157]. Similarly, constitutive activation of STAT5 
by the SFK, Hyk, resulted in cytokine-independent cell growth in cytokine-
dependent leukemic cells [158]. STAT5 activation is also associated with chronic-
to-blast crisis phase transition in leukemia patients. As indicated previously, in up 
to 95% of AML blast cells constitutive activation of STAT3 and STAT5 could be 
detected [151].  
Interestingly, increased STAT5 activation in BCR-ABL-positive leukemic 
cells and STAT5’s ability to confer resistance to dasatinib has been shown to be 
directly correlated with leukemic cell density [159]. This recent study revealed 
that an increase in the density of leukemic cells resulted in a decrease in 
dasatinib’s efficacy against STAT5-mediated signaling. Results indicate that this 
observation may attribute to the upregulation of STAT5-regulated anti-apoptotic 
proteins. 
Taken together, this demonstrates that constitutive STAT5 activation 
promotes CML pathogenesis and imatinib resistance by up-regulating the 
expression of anti-apoptotic proteins, Bcl-x, Mcl-1 and cyclin D1. Additionally, 
enhanced STAT5 activation is capable of mediating cytokine-independent growth 
in leukemic cells, leading to increased cell survival. 
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CHAPTER VII 
OBJECTIVES 
 
The BCR-ABL fusion gene is critical for the development of CML. 
Treatment with imatinib is highly effective against CML; however treatment 
response in patients is compromised by the emergence of imatinib resistance. In 
vitro resistance models often fail to consider the role of the tumor 
microenvironment in the emergence of imatinib resistance. The predominant 
microenvironment of CML is the bone marrow, a rich source of both soluble 
factors and extracellular matrixes which may influence drug response. This study 
was developed to address the influence of the bone marrow microenvironment 
on imatinib sensitivity. We utilized an in vitro co-culture bone marrow stroma 
model to demonstrate that stable soluble factors secreted by the HS-5 human 
bone marrow stroma cell line were sufficient to protect K562 CML cells against 
imatinib-induced cell death. Subsequently, we observed that HS-5-derived 
conditioned media (CM) also provided protection against cell death. Previous 
studies showed that HS-5 stromal cells secrete cytokines and growth factors 
involved in the growth and differentiation of hematopoietic stem cells [160]. Some 
of these cytokines are capable of activating signal transduction pathways 
involved in myeloid differentiation. Investigations into the activation of survival 
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pathways that reconstitute BCR-ABL signaling in CM may provide novel insights 
into the mechanism of environment-mediated drug resistance (EMDR). One such 
pathway being investigated is the signal transducer and activator of transcription 
3 (STAT3) survival pathway. A review of the current literature led to the following 
hypothesis: 
Bone marrow-derived soluble factors in conditioned media contribute to 
the failure of BCR-ABL inhibitors to eradicate minimal residual disease 
CML. 
In order to refute or support this hypothesis, the following objectives were 
formulated: 
 
1. To determine if HS-5-derived CM protects CML cell lines from death 
induced by second generation BCR-ABL inhibitors 
2. To determine whether HS-5-derived CM increased the proliferation and 
clonogenic survival of CML cells 
3. To determine whether HS-5-derived CM mediate the activation of STAT3 
and STAT5 cell survival pathways in CML cells 
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CHAPTER VIII 
MATERIALS AND METHODS 
 
Cell Cultures 
Human CML K562 and KU812 cells (obtained from the American Type Culture 
Collection) were cultured in RPMI 1640 supplemented with 10% fetal bovine 
serum, 1% L-glutamine, and penicillin/streptomycin [regular medium (RM); Life 
Technologies] at 37°C in 5% CO2 in a humidified incubator. The human stromal 
cell line HS-5 (also obtained from the American Type Culture Collection) was 
maintained under the same conditions. 
Generation of Conditioned Media (CM) 
CM was generated by culturing 5 x 105 HS-5 cells/mL in RM overnight in a 
humidified atmosphere at 37°C with 5% CO2 to achieve 75% to 80% confluency. 
Subsequently, the medium was removed and the cells were incubated in fresh 
medium for 3 hours. The supernatant was then collected and cleared of 
contaminating cells by centrifuging at 2,000 rpm for 5 minutes. Supernatant was 
aliquoted and stored at -80°C for future use. 
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Drugs and Reagents 
Imatinib mesylate and nilotinib (AMN107), supplied by Novartis Pharma, were 
dissolved in DMSO as a 10 mM stock solution and stored in aliquots at -20°C. 
Dasatinib, supplied by Bristol-Myers Squibb, was treated similarly. 
Treatment with Tyrosine Kinase Inhibitors 
Preparation of Lysates and Western Blotting 
K562 or KU812 cells were cultured at a density of 4 x 105/mL in either RM or CM 
for various time points in the presence or absence of either a matched vehicle 
control (DMSO) or drug (imatinib or dasatinib). Subsequently, cells were pelleted 
and lysed in radioimmunoprecipitation assay lysis buffer supplemented with 
phosphatase and protease inhibitors (1 mM Na3VO4, 1 mM NaF, 1 mM 
phenylmethylsulfonyl fluoride, 10 µg/mL leupeptin, and 10 µg/mL aprotinin). 
Insoluble materials were removed by centrifugation at 4°C for 20 minutes at 
15,000 rcf . Antibodies used for Western blotting were anti-STAT3, anti-STAT3 
(Tyr705), anti-Bcl-xl, anti-Mcl-1, anti-Survivin, and p-SRC (all from Cell Signaling 
Technologies). 
Apoptosis Assay 
Apoptosis was measured using the Annexin V-FITC apoptosis detection kit 
(Alexis Biochemicals) according to the manufacturer’s recommendations. Data 
were acquired using CellQuest Pro software version 4.0.2 (BD Biosciences) and 
analyzed using FlowJo software version 7.2.2 (Tree Star). 
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siRNA Transfection 
K562 cells cultured in RM were transiently transfected with either STAT3 siRNA 
(siGENOME ON-TARGETplus SMARTpool reagent; Dharmacon) or a control 
siRNA (ONTARGETplus siCONTROL Nontargeting reagent; Dharmacon) using 
Amaxa Nucleofector methodology (Amaxa). Briefly, 1 x 106 K562 cells were 
transfected per manufacturer’s instructions. Thirty-six hours post-transfection, the 
process was repeated to ensure continued suppression of STAT3 levels. 
Transfected K562 cells (2.0 x 105/mL) were then cultured in RM or CM for 3 
hours then treated with 250 nM imatinib or a vehicle control (DMSO). Cell death 
was measured using Annexin V apoptosis assay as described previously. 
Bromodeoxyuridine (BrdU) Antibody Staining  
2.5 x 105 K562 cells/mL were cultured in RM or CM for 24 hours then pulsed with 
30 µg/mL 5-bromo-2-deoxyuridine (BrdU) for 30 minutes. Cells were fixed with 
ethanol and BrdU incorporation was detected using FITC-conjugated anti-BrdU 
antibody (Calbiochem, Gibbstown, NJ). Data acquisition and analysis were done 
using fluorescence-activated cell sorting (FACS). 
Clonogenic Assay 
K562 cells were diluted to a concentration of 10,000 cells/mL in RM or  CM for 6 
hours in the absence or presence of imatinib and incubated at 37°C with 5% 
CO2. Cells are transferred to 0.3% final agar solution reconstituted in RM or CM. 
Once the agar solidifies, cells were allowed to incubate for 8-10 additional days. 
Cell colonies (>50 cells) were then counted on 2 mm grid culture dish (Corning). 
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Preparation of Nuclear Extracts 
Nuclear extracts were prepared by resuspending 5 x 106 K562 cells in hypotonic 
buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 
0.2 mM PMSF, 2 µg/mL leupeptin, 0.15 µg/mL aprotinin) followed by incubation 
on ice 5 minutes. Cells were centrifuged for 10 seconds at 14000 rpm and 
washed once with hypotonic buffer. The nuclei were collected by centrifugation 
for 5 minutes at 14000 rpm and washed once with hypotonic buffer.  The nuclear 
pellet was resuspended in 50 µL of hypertonic buffer (20 mM HEPES-KOH, pH 
7.9, 25% glycerol, 450 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM 
dithiothreitol, 0.5 mM PMSF, 2 µg/mL leupeptin, 0.15 µg/mL aprotinin), incubated 
for 30 minutes at 4ºC followed by centrifugation for 2 minutes at 14000 rpm. 
Electrophoretic Mobility Shift Assay (EMSA) 
A total of 2 µL nuclear extract was incubated with a double-stranded 32P-labeled 
oligonucleotide (1 ng) sis-inducible element (SIE), (5’-
TCGAGTATTTCCCAGAAAAGGAACAGCT-3’ and its complement) in 10 µL 
binding buffer (25 mM HEPES, pH 7.9, 100 µM ethylene glycol tetraacetic acid 
(EGTA), 200 µM MgCl2, 500 µM dithiothreitol, 1 µg/mL BSA, 0.2 µg/mL poly 
dI:dC) for 15 minutes at room temperature. Protein-DNA complexes were 
detected by autoradiography and quantified using a phosphoimager. 
MTT Assay.  
Incubate 50,000 K562 cells/ mL for 3 hours in either regular media or conditioned 
media. Add varying concentrations of imatinib. Incubate drug-treated cells for 72 
  64 
hours at 37°C, 5% CO2. Add MTT dye and incubate for 3 hours at 37°C, 5% CO2. 
Read absorbance at 540 nm on a spectrophotometer. 
Statistical Analysis 
A preliminary examination of the data was done using descriptive summary 
analysis and the Anderson-Darling statistic. Significance testing of the dose-
response apoptosis assays was done using analysis of covariance. The 
Student’s t test was used for the siRNA experiments to compare the log-
transformed fold change values, with the null hypothesis being a log (fold 
change) = 0 (or conversely the fold-change = 1). A significance level of 0.05 was 
considered statistically significant for all tests. The geometric means of the four 
ratios for siRNA experiments and the 95% confidence intervals were also 
calculated  
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RESULTS 
 
Co-culture Bone Marrow Stromal Model Protects K562 CML Cells from 
Imatinib-Induced Apoptosis 
Previous work done by Torok-Storb et. al. revealed that HS-5 human 
stromal cells are capable of producing cytokines and growth factors that are 
involved in the growth and differentiation of HSC and are also capable of 
supporting the ex vivo expansion of both immature and mature progenitor cells 
[160]. To test our hypothesis that the bone marrow microenvironment contributes 
to the failure of BCR-ABL inhibitors to eradicate minimal residual disease CML, 
we utilized a co-culture bone marrow microenvironment transwell model system 
and took advantage of HS-5 stroma cells’ ability to support HSC and their 
progenitors. We wanted to determine whether the bone marrow 
microenvironment protects the K562 CML cell line, which originated from the 
pleural effusion of a CML female patient in terminal blast crises phase, from 
death induced by imatinib.  
Using this co-culture model, we first wanted to delineate the contributions 
of (1) HS-5-derived soluble factors alone, and (2) direct adhesion to HS-5 cells 
on imatinib resistance in K562 CML cells treated with 1 µM of imatinib (Figure 
14). Our control samples consisted of K562 cells cultured in regular media (RM). 
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Here we saw approximately 35% cell death. Next, we determined the effects of 
transiently secreted soluble factors on K562 cells cultured in the upper chamber 
of the transwell (TSF), and here we saw protection from cell death at 
approximately 10%. We then examined the effects that direct adhesion to HS-5 
stroma cells as well as secreted soluble factors on imatinib-induced K562 cell 
death (SF+A). Here we observed an even greater protection from cell death at 
5%. Lastly, we examined the effects of HS-5-derived stable soluble factors alone 
on apoptosis by using HS-5 conditioned media (CM). Here we saw 15% cell 
death. Taken together, these data revealed that the co-culture model was not 
required for the production of the protective soluble factors produced by HS-5. It 
also revealed that HS-5 conditioned media contained stable soluble factors that 
provided protection against imatinib-induced cell death. Therefore, to simplify our 
bone marrow stroma model, we utilized HS-5-derived conditioned media in our 
subsequent experiments. 
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Figure 14: Co-culture Bone Marrow Transwell Stromal Model. (A) Co-culture 
transwell model system of K562 chronic myeloid leukemia (CML) cultured in: i) 
regular media (RM: RPMI + 10% FBS, 1% Penicillin /Streptomycin); ii) the upper 
chamber of the transwell system with HS-5-secreting transient soluble factors 
(TSF) or with direct adhesion to HS-5 stroma cells (SF+A); iii) .HS-5-derived 
conditioned media (CM: RM collected after 3-hour incubation with HS-5 cells). 
(B) Annexin V apoptosis assay of conditions described in A. 
Characterizing Conditioned Media  
Collecting Conditioned Media beyond 3 Hours does not Provide Greater 
Protection against Imatinib-Induced Cell Death 
To verify whether 3-hour HS-5-derived conditioned media provided the 
best protection against imatinib-induced cell death, we generated the conditioned 
media as described before, however, instead of only collecting at 3 hours it was 
collected at varying time-points: 1, 3, 6 and 24 hours.  
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As seen in Figure 15, our data revealed that conditioned media generated 
beyond 3 hours did not provide greater protection from death induced by 500 nM 
of imatinib. 
 
Figure 15: The Effects of Conditioned Media Collected at Various Times on 
Imatinib-Induced Cell Death in K562 CML Cells. HS-5 stromal cells cultured to 
75-80% confluency in regular media were incubated for 1, 3, 6, 24 hours in fresh 
media. Cell death was measured using the Annexin V apoptosis assay following 
treatment with 500 nM of imatinib for 48 hours. Results were analyzed using flow 
cytometry. 
Conditioned Media Stored for up to One Week Still Provided Protection 
against Imatinib-Induced Cell Death 
To determine the effects of storage on the protective characteristic of 3 
hour-derived conditioned media, we cultured K562 cells in regular media and 
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conditioned media that was freshly collected, one day and one week old. One-
day and one-week old conditioned media were stored at -80°C.  
After treating K452 cells with 500 nM of imatinib, our results were 
analyzed with Annexin V apoptosis assay. Figure 16 reveals that 3-hour-derived 
conditioned media that was stored at -80°C for up to one week could still protect 
K562 CML cells from death induced by imatinib. This confirmed that HS-5-
derived soluble factor(s) in the conditioned media is stable and does not have a 
short half-life. To ensure consistency and preserve the integrity of our data, we 
did not store conditioned media for longer than one week. 
 
Figure 16: The Effects of Storage on 3-Hour-Derived Conditioned Media. To 
make the time-dependent conditioned media, HS-5 stromal cells were grown to 
75-80% confluency in regular media (RM) for 3 hours. Media was then collected 
and used fresh, after one day of storage at -80°C or after one week of storage. 
Cell death was measured using the Annexin V apoptosis assay following 
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treatment with 500 nM of imatinib for 48 hours. Results were again analyzed 
using flow cytometry. 
Serum is not Required for Production of the Protective Soluble Factor(s) 
Found in HS-5-Derived Conditioned Media 
We next wanted to determine if HS-5 human stromal cells require serum 
to produce the activate component in conditioned media. To answer this question 
we examined whether serum-free conditioned media (SF-CM) can still protect 
K562 cells from apoptosis induced by imatinib. HS-5 stromal cells were allowed 
to incubate for 3 hours in regular media void of serum. This SF-CM was then 
collected and supplemented with 10% FBS then utilized in our experiments. As 
before, K562 cells were cultured in regular media (RM), conditioned media (CM) 
and SF-CM. Our results were analyzed using the Annexin V apoptosis assay 
followed by flow cytometry analysis.  
As seen in Figure 17, HS-5 stromal cells were capable of producing their 
protective soluble factor(s) in the absence of FBS. Additionally, since media 
containing serum is more difficult to fractionate, these data demonstrates that 
future studies to identify the protective component of conditioned media using 
fractionation can be readily accomplished with this SF-CM. 
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Figure 17: The Effects of Serum-Free Conditioned Media on Imatinib-
Induced K562 Cell Death. To make the time-dependent serum-free (SF) 
conditioned media, HS-5 stromal cells were grown to 75-80% confluency in 
regular media (RM) for 3 hours. Media was then collected and 10% fetal calf 
serum (FBS) was added. SF-CM was used fresh, after one day of storage at -
80°C or after one week of storage. Cell death was measured using the Annexin V 
apoptosis assay following treatment with 500 nM of imatinib for 48 hours. Results 
were again analyzed using FACS. 
Conditioned Media does not Convey a Growth Advantage to K562 CML 
Cells  
Given our previous results which show that conditioned media protects 
K562 cells from death induced by imatinib within our bone marrow stromal 
model, we decided to investigate whether conditioned is capable of increasing 
the rate of K562 cell proliferation and DNA synthesis. 
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Using trypan blue exclusion staining method, Figure 18A shows that when 
cells were counted over the course of six days, there was no increase in cell 
proliferation in K562 cells regardless of culture conditions.  
To verify these results, the rate of DNA synthesis, which is indicative of 
cell proliferation, was also measured via BrdU incorporation staining and 
detection with a FITC-conjugated anti-BrdU antibody. Figure 18B shows that 
DNA synthesis is also not increased in conditioned media. Figure 18C is a 
representative of three independent BrdU incorporation staining assays. 
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Figure 18: The Effects of Conditioned Media on K562 Cell Proliferation and 
DNA Synthesis. (A) 50,000 K562 cells were cultured in regular media or 
conditioned media and total cell count was determined every 24 hours using 
trypan blue exclusion staining. Results and standard deviation represents the 
average of 4 independent experiments. (B) The rate of DNA synthesis was 
determined by 5-bromo-2-deoxyuridine (BrdU) antibody staining. 2.5 x 105 K562 
cells/mL were cultured in regular media or conditioned media for 24 hours then 
pulsed with 30 µg/mL of BrdU for 30 minutes. Cells were then fixed with ethanol 
and BrdU incorporation was detected using FITC-conjugated anti-BrdU antibody. 
Data acquisition and analysis were done using FACS. (C) Representative figure 
of BrdU incorporation staining (n=3). 
Heat-Inactivated Conditioned Media does not Protect against Imatinib 
Mesylate-Induced Cell Death 
Cytokines are proteins that initiate cellular communication. To determine if 
the HS-5-derived protective soluble factor(s) found in conditioned media is a 
cytokine we cultivated K562 CML cells in regular media and heat-inactivated 
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conditioned media, treated them with 500 nM imatinib for 48 hours then 
performed an Annexin V apoptosis to determine cell death. Results were 
analyzed via FACS. 
Figure 19 shows that when K562 CML cells were cultured in heat-
inactivated conditioned media there was no protection from death induced by 
imatinib. This demonstrates that the protective soluble factor in HS-5 conditioned 
media is a protein. 
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Figure 19: Heat-Inactivated Conditioned Media does not Protect K562 Cells 
Against Imatinib-Induced Cell Death. K562 cells were cultured for 3 hours in 
either regular media or conditioned media that was heat-inactivated at 95°C for 
10 minutes. Cells were treated with 500 nM imatinib or 0.1% DMSO for 48 hours. 
Cell death was measured using Annexin V apoptosis assay followed by 
fluorescence-activated cell sorting analysis.  
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HS-5-Derived Conditioned Media Protects K562 and KU812 CML Cell Lines 
from Death Induced by Imatinib Mesylate 
Results from our co-culture bone marrow stromal model had revealed that 
HS-5 conditioned media alone can also protect K562 CML cells from imatinib-
induced cell death. We wanted to determine whether the effects we saw was cell 
line specific by doing a dose response profile. To address this question, we 
performed an imatinib-dose response profile using the CML cell lines, K562 cells 
and KU812, which is a pre-basophilic cell line that originated from the peripheral 
blood of a CML patient in blast crisis phase. Cells were cultured in regular media 
or conditioned and treated with increasing doses of imatinib (0, 125, 250, 500 nM 
imatinib) for 48 hours.  
The results of the Annexin V apoptosis revealed that exposing either K562 
or KU182 cells to conditioned media for 3 hours before drug treatment was 
sufficient to inhibit apoptosis induced by imatinib (Figures 20A and B) and 
suggested that the protective effects of conditioned media is not cell-line specific.  
Additionally, we performed a clonogenic assay, or colony formation assay, 
to determine whether conditioned media increased the ability of K562 cells to 
divide and form colonies. The clonogenic assay is an in vitro cell survival assay 
based on the ability of a single cell to grow into a colony. It is a measure of 
cancer cells’ ability to repopulate and form colonies in semisolid media. The 
colony is defined to consist of at least 50 cells.  
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First, we wanted to determine the optimal K562 cell concentration to use 
for the clonogenic assay. To determine this, we performed clonogenic assays 
using varying concentrations of K562 cells to obtain a cell-density profile. As 
shown in Figure 20C, in the absence of imatinib, conditioned media did not 
increase the clonogenic survival of K562 cells across the differing cell 
concentrations indicated. Additionally, in the absence of imatinib, the initial cell 
concentrations of 2,500 and 5,000 cells provided too few colonies at the end of 
10 days to justify the use of these concentrations. Therefore, we utilized the initial 
cell concentration of 10,000 cells in our subsequent clonogenic assays to ensure 
that there would be enough viable colonies to count, even after high-dose 
imatinib treatment.  
Figure 20D shows that when K562 cells are treated with varying 
concentrations of imatinib, the clonogenic survival of those cells cultured in 
conditioned media was increased across all imatinib concentrations when 
compared to those control cells cultured in regular media. Taken together, these 
data indicate that not only does conditioned media protect from imatinib-induced 
apoptosis or cell death but also results in a higher percentage of cells capable of 
dividing and repopulating.  
Finally, as shown in Figure 20E, removal of K562 cells from conditioned 
media into regular media partially reverses resistance to imatinib-induced cell 
death. This suggests that imatinib-resistance in CML cells occurs in the presence 
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of HS-derived soluble factors and in the absence of the soluble factors CML cells 
become re-sensitized to the apoptotic effects of imatinib. 
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Figure 20: HS-5-Derived Conditioned Media Protects K562 and KU182 CML 
Cells from Death Induced by Imatinib. (A) K562 or (B) KU182 cells were 
cultured in either regular media or conditioned media for 3 h and before the 
addition of various concentrations of imatinib or 0.1% DMSO for 36 hours. Cell 
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death was measured using Annexin V apoptosis assay followed by fluorescence-
activated cell sorting analysis. % Drug-specific apoptosis was calculated by 
subtracting the background cell death in control DMSO-treated cells from drug 
treated cell death. A, Conditioned media significantly protects K562 cells from 
imatinib-mediated cell death (P < 0.05, analysis of covariance). B, Conditioned 
media significantly protects KU182 cells from imatinib-mediated cell death (P < 
0.05, analysis of covariance). C, Cell-density profile of K562 cells shows similar 
clonogenic survival in regular media and conditioned media. K562 cells were 
cultured in regular media or conditioned media without imatinib. After 6 hours 
incubation at 37°C, 5% CO2, cells were cultured in 0.3% agar made of regular 
media or conditioned media and containing their respective imatinib 
concentrations. Cells were allowed to incubate at 37°C, 5% CO2 for 10 days. Cell 
colonies (>50 cells) were counted. Representative figure in triplicate (n = 3 
independent experiments). The starting concentration of 10,000 cells was used in 
subsequent clonogenic assays. D, Conditioned media increases the clonogenic 
survival of K562 CML cells treated with imatinib. K562 cells were cultured in 
regular media or conditioned media and treated with increasing concentrations of 
imatinib as depicted. After 6 hours incubation at 37°C, 5% CO2, cells were 
cultured in 0.3% agar made of regular media or conditioned media and 
containing their respective imatinib concentrations. Cells were allowed to 
incubate at 37°C, 5% CO2 for 10 days. Cell colonies (>50 cells) were counted. 
Representative figure in triplicate (n = 3 independent experiments). E, Removal 
of conditioned media partially reverses resistance to imatinib (P < 0.05, Student t-
test). K562 cells were grown in either conditioned media or regular media for 3 
hours. Following 3 hours, appropriate samples were removed from conditioned 
media and placed in regular media for an additional 3 hours. Cells were treated 
with 500 nmol/L imatinib for 36 hours and apoptosis was measured by Annexin V 
positivity. Representative figure of experiments done in triplicates. 
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Conditioned Media from Non-Stromal Cell Lines do not Protect K562 CML 
Cells from Death Induced by Imatinib Mesylate 
 Some cells are capable of secreting their own soluble factors via an 
autocrine loop and condition their own media. We investigated whether the 
protection against cell death that we observed using HS-5-derived conditioned 
media was specific to this human stromal cell type. To address this, we 
generated conditioned media from several other non-stromal cells. K562 CML 
cells, U937 lymphoma cells and 8226 myeloma cells were incubated in regular 
media for three hours, after which their conditioned media was collected. To 
perform the experiment, K562 cells were cultured for three hours in regular 
media and the conditioned media of the different cell lines previously described. 
The cells were then treated with 500 nM of imatinib for 48 hours. An Annexin V 
apoptosis assay was performed followed by flow cytometry analysis. 
As you can see in Figure 21, there was no protection from imatinib-
induced cell death in K562 cells cultured in its own conditioned media, as well as 
in conditioned media from U937 and 8226 cell lines. This suggests that the 
secreted, protective soluble factor(s) responsible for conferring the imatinib-
resistant phenotype are specific to bone marrow stromal cells.  
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Figure 21: Conditioned Media from Non-Stroma Cell Lines does not Protect 
K562 CML Cells from Death Induced by Imatinib. K562 cells were cultured for 
3 hours in either regular media or conditioned media generated from K562, U937 
and 8226 cell lines. Cells were treated with 500 nM imatinib or 0.1% DMSO for 
48 hours. Cell death was measured using Annexin V apoptosis assay followed by 
fluorescence-activated cell sorting analysis.  
Conditioned Media Protects K562 CML Cells from Death Induced by 2nd 
Generation BCR-ABL Inhibitors, Nilotinib and Dasatinib 
One of the shortcomings of imatinib therapy stems from the fact that, over 
the course of treatment, many patients develop resistance which results in 
relapse and disease progression. Studies have shown that imatinib resistance is 
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often caused by point mutations in the BCR-ABL tyrosine kinase domain [113, 
161]. This discovery has led to the design and development of more potent, 
second generation kinase inhibitors that target imatinib-resistant BCR-ABL 
mutants. Dasatinib (Sprycel, BMS-354825, Bristol-Myers Squibb) and nilotinib 
(AMN107) represent two potent second-generation BCR-ABL inhibitors, both of 
which are more potent than imatinib and show considerable efficacy against most 
of the well-characterized BCR-ABL mutants. Both imatinib and nilotinib bind to 
the inactive conformation of BCR-ABL, although nilotinib was designed to provide 
a better topological fit to the enzyme’s tyrosine kinase domain and binds with 
approximately thirty times higher affinity than imatinib. In contrast, dasatinib binds 
both the active and inactive conformations of BCR-ABL kinase due to its less 
stringent conformational requirements for binding and it is a less selective kinase 
inhibitor, targeting SRC kinase family members as well. It is approximately 300 
times potent than imatinib against wild-type BCR-ABL expressing cells and, 
therefore, inhibits BCR-ABL kinase activity at low-nanomolar concentration 
(between 0.75 to 1.0 nM).  
As shown in Figures 22A and B, conditioned media protects from both 
nilotinib- and dasatinib-induced cell death. These data indicate that the 
development of more potent BCR-ABL inhibitors will not circumvent resistance 
associated with exposure of CML cells to soluble factors produced by the bone 
marrow microenvironment.  
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Figure 22: HS-5-Derived Conditioned Media Protects K562 CML Cells from 
Death Induced by 2nd Generation BCR-ABL Inhibitors, Nilotinib And 
Dasatinib. K562 cells were allowed to incubate for either 48 hours (nilotinib) or 
24 hours (dasatinib). Conditioned media significantly protects K562 cells from (A) 
nilotinib-mediated cell death (P < 0.05, analysis of covariance) and (B) dasatinib- 
mediated cell death (P < 0.05, analysis of covariance). Representative graph in 
triplicates (n = 2 independent experiments) 
Conditioned Media Activates STAT3 in K562 and KU812 CML Cell Lines 
Signal transducers and activators of transcription (STATs) are members of 
a family of transcription factors that were originally characterized as mediators of 
cytokine- and growth factor-induced signaling. Many of the growth factors and 
cytokines reported to be expressed in the HS-5 cell line are known activators of 
STAT3 and STAT5, including granulocyte-macrophage colony-stimulating factor, 
G-CSF, interleukin-6, and vascular endothelial growth factor [162-167]. Thus, to 
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determine the mechanism(s) of drug resistance observed in conditioned media, 
we decided to exam the roles of both STAT3 and STAT5 within our bone marrow 
stromal model. We first examined the effects of conditioned media on STAT3 
activation. We wanted to determine whether culturing K562 cells in conditioned 
media caused an increase in the phosphorylation of STAT3.  
To address this question, we performed Western blotting of K562 and 
KU812 CML cell lines cultured in regular media or conditioned media across 
various time points and used antibodies to probe for pTyr705-STAT3. Total 
STAT3 and β-actin serve as loading controls. As shown in Figures 23A and B, a 
rapid and sustained increase in pTyr705-STAT3 levels is observed across the 
indicated time points in both K562 and KU182 cells cultured in conditioned media 
as compared to those cells cultured in regular media. This suggests that our 
drug-resistant phenotype may be due to the anti-apoptotic affects of increased 
STAT3 activation and also demonstrates that our results were not cell-line 
specific.  
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Figure 23: STAT3 Phospho-Y705 is Increased in K562 and KU812 CML Cells 
Cultured in Conditioned Media. (A) K652 cells were cultured in regular media 
or conditioned media for the time points indicated. Cells were collected, lysed, 
and analyzed for either pTyr705 or total STAT3 via Western blotting. β-actin was 
used as a loading control. (B) KU812 cells were cultured in RM or CM for the 
time points indicated. Cells were collected, lysed, and analyzed for either 
pTyr705 or total STAT3 via Western blotting. β-actin was used as a loading 
control. Representative figure (n = 3 independent experiments). 
STAT3 Activation in CML Cells is BCR-ABL-Independent  
Previous studies have shown that BCR-ABL activates STAT3 by 
phosphorylating Ser727 via the MEK pathway [168]. To determine whether 
conditioned media-mediated STAT3 activation in CML cells is BCR-ABL 
dependent, we cultured K562 cells in regular media or conditioned media for 3 
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hours, then inhibited BCR-ABL signaling by treating cells with varying doses of 
imatinib for 48 hours. Cells were subsequently lysed followed by Western blotting 
for p-Y705 STAT3 and total STAT3 as a loading control. 
We see in Figure 24 that treating K562 cells cultured in conditioned media 
with increasing concentrations of imatinib did not reduce STAT activation. In fact, 
there is an increase in the basal levels of p-Y705 STAT3 in cells grown in 
conditioned media when compared to those cultured in regular media and there 
is also sustained STAT3 activation in the presence of imatinib. This data lends 
greater support to our previous findings that our drug-resistant phenotype may be 
due to the anti-apoptotic affects of increased, aberrant STAT3 activation in CML 
cells cultured in conditioned media. 
 
Figure 24: Basal Phospho-Y705 STAT3 is Increased in K562 CML Cells 
Cultured in Conditioned Media and is Sustained in the Presence of 
Imatinib. K562 cells were cultured in regular media or conditioned media for 3 
hours prior to treating cells with varying doses of imatinib for 48 hours and 
followed by Western blotting for pSTAT3 and total STAT3.  
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STAT5 activation is BCR-ABL-dependent  
Previous work done by de Groot revealed that BCR-ABL-mediated STAT5 
activation can contribute to K562 leukemic cells’ transformation [169]. To 
investigate the potential contribution of STAT5 activation in our drug resistant 
phenotype seen in conditioned media, we decided to also examine whether 
STAT5 activation in our model is BCR-ABL dependent. As before, we cultured 
K562 cells in regular media or conditioned media for 3 hours, inhibited BCR-ABL 
signaling with varying doses of imatinib for 48 hours and performed Western 
blotting for p-Y694 STAT5, with total STAT5 used as a loading control. 
In contrast to our observations with STAT3, culturing K562 cells in 
conditioned media did not increase the basal levels of pSTAT5 (Figure 25). 
Furthermore, pSTAT5 levels were equally inhibited regardless of the culture 
condition. This indicates that STAT5 activation is BCR-ABL-dependent and 
eliminates STAT5 as a mediator in the drug-resistant phenotype conveyed by 
conditioned media. 
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Figure 25: K562 Cells Cultured in Conditioned Media Show Equal Levels of 
Phospho-Tyr STAT5 and Equal Inhibition of Phospho-Tyr STAT5 after 
Imatinib Treatment. K562 cells were cultured in regular media or conditioned 
media for 3 hours; cells were treated with varying doses of imatinib for 48 hours 
and probed for pSTAT5 and total STAT5 via Western blotting. 
STAT3 Activation is not SRC-Dependent 
Previous studies have shown that STAT3 activation can occur via 
activation of c-SRC, a member of the proto-oncogenic tyrosine kinases [170]. To 
examine whether STAT3 activation within our model is also being mediated by 
SRC, we cultured K562 cells in regular media or HS-5-derived conditioned 
media, then treated the cells with increasing concentrations of the dual BCR-
ABL/SRC-kinase inhibitor, dasatinib, for 24 hour, followed by Western blotting for 
pY705 STAT3 and p-SRC. Total STAT3 and GAPDH were used as loading 
controls. 
Work done in our lab revealed that while dasatinib inhibited p-SRC 
activity, it did not have any inhibit p-Y705 STAT3 activity (Figure 26). This 
suggests that STAT3 activation in conditioned media is also independent of SRC 
activity. 
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Figure 26: Dasatinib Inhibited Phospho-SRC Activity but not Phospho-Y705 
STAT3 Activity. Treating K562 CML cells with dasatinib inhibited levels of p-
SRC family members but did not attenuate the levels of pSTAT3 when K562 cells 
were cultured in CM. K562 cells were grown in regular media or conditioned 
media, and then treated with increasing doses of the dual BCR-ABL/SRC-kinase 
inhibitor, dasatinib, for 24 hours. This was followed by Western blotting for p-
Y705 STAT3 and p-SRC. Total STAT3 and GAPDH were used as loading 
controls. Representative figure (n = 3 independent experiments). 
Protein Expression Levels of STAT3 Downstream Targets are Increased in 
K562 Cells Cultured in Conditioned Media 
We next examined whether increased activation of STAT3 corresponded 
with an increased expression of its downstream targets, Bcl-xL, Mcl-1 and 
survivin.  
Previous reports indicated that inhibition of BCR-ABL results in decreased 
expression of STAT5-regulated genes including Bcl-xL (24). As shown in Figure 
27, while basal levels of Bcl-xL, Mcl-1 and survivin were not increased in K562 
cells cultured in conditioned media compared to those cultured in regular media 
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(0 nM imatinib), when those cells were treated with imatinib in the context of 
conditioned media these protein expression levels were sustained. Specifically, 
we observed that, in the presence of 500 nmol/L imatinib, Bcl-xl, Mcl-1, and 
survivin were increased by 4.19 ± 1.82, 3.48 ± 1.84, and 7.0 ± 3.41, respectively 
(n = 3 independent experiments) when cells were cultured in conditioned media 
compared with cells cultured in regular media. These data suggest that activation 
of STAT3 may be responsible for persistent expression of STAT-regulated genes 
despite inhibition of STAT5 following imatinib treatment. 
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Figure 27: The Effects of Conditioned Media on STAT3 Downstream 
Targets, Bcl-Xl, Mcl-1 and Survivin. K562 CML cells were cultured in regular 
media or conditioned media for 3 hours then treated with imatinib in a dose-
dependent manner for 48 hours. Western blot analysis was done with specific 
antibodies to Bcl-xl, Mcl-1, and survivin as described in Materials and Methods. 
Western blots showing: (A) Bcl-xl; (B), Mcl-1; and (C), survivin. β-actin was used 
as a loading control. Representative figure (n = 3 independent experiments). 
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Reducing STAT3 Levels with siRNA Increases Sensitivity to Imatinib 
Mesylate in Conditioned Media 
SiRNA technology was used to determine the causative role for activation 
of STAT3 with respect to mediating resistance to imatinib when K562 cells were 
cultured in conditioned media. Figure 27A depicts the timeline used in performing 
these time-course experiments.  
As shown in Figure 28B, STAT3 was reduced at 84 hours and remained 
reduced for 120 hours. Based on these time-course experiments, apoptotic 
assays were designed as follows: K562 CML cells were transfected with either a 
control siRNA or STAT3 siRNA and this process was repeated 36 hours later to 
ensure that STAT3 gene expression remained silenced; 84 hours following 
imatinib treatment, control siRNA and STAT3 siRNA-transfected cells were 
treated with either 250 nmol/L imatinib or vehicle control for 36 hours (120 h after 
initial transfection with siRNA) and apoptosis was detected by Annexin V binding. 
Because some tumor types require STAT3 for survival, we first analyzed whether 
reducing STAT3 levels with siRNA was sufficient to induce apoptosis when cells 
were cultured in either regular media or conditioned media. As shown in Figure 
28C, reducing STAT3 levels (120 hours time point) with siRNA did not cause 
apoptosis in either growth condition. However, reducing STAT3 levels sensitized 
K562 to imatinib-induced cell death when K562 cells were grown in conditioned 
media but not in regular media (see Figure 28D for a representative figure).  
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In Figure 28E we graphed the geometric mean of the ratios of each group 
depicted, showing the 95% confidence intervals and the P-values. We used the 
geometric mean instead of the arithmetic mean because with the arithmetic 
mean values below 1 are limited to numbers between 1 and 0. But values above 
1 are limited to 1 and infinity. Therefore, using the geometric mean enabled us to 
address this asymmetry. The first group we analyzed was those cells transfected 
with the control siRNA and treated with imatinib regardless of culture conditions.  
Our results in Figure 28E show that in the control siRNA-transfected cells, 
there was a significant difference in imatinib-specific cell death seen in K562 cells 
cultured in regular when compared to those cultured in conditioned media. We 
next analyzed the STAT3 siRNA-transfected cells that were treated with imatinib 
in either regular media or conditioned media. Our results show that when STAT3 
is knocked-down using siRNA there was no significant difference in imatinib-
induced apoptosis in cells cultured in regular media compared to those cultured 
in conditioned media. In essence, we were able to reverse the drug-resistant 
phenotype seen in conditioned media by knocking-down STAT3. We then 
analyzed those cells cultured in regular media, regardless of their transfection 
state. As seen in Figure 28E, our results show that when cultured in regular 
media, whether or not STAT3 is knocked-down, there was no significant 
difference in apoptosis induced by imatinib. Lastly, we analyzed those cells 
cultured in conditioned media, regardless of their transfection state. Our results 
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show that when cultured in conditioned media and STAT3 is knocked-down, 
there was a significant difference in apoptosis induced by imatinib.  
Taken together, these data indicate that STAT3 contributes to imatinib 
resistance only when cells are cultured within the context of bone marrow 
stroma-derived conditioned media. Furthermore, these data suggest that STAT3 
can compensate for BCR-ABL survival signals and thus represents a potential 
BCR-ABL-independent mechanism of drug resistance.  
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Figure 28: Reducing STAT3 Levels with siRNA Reverses Imatinib 
Resistance in K562 Cells Cultured in Conditioned Media. K562 cells were 
cultured in either regular media or conditioned media and treated with either 
siRNA to STAT3 or control siRNA. (A), Time line for conducting siRNA 
experiments. (B), STAT3 knockdown was confirmed using Western blotting and 
STAT3 was noted to be maximally decreased at 84 hours and remained reduced 
for at least 120 hours (n = 5 independent experiments). (C), reducing STAT3 
levels was not sufficient to cause cell death in cells cultured in regular media or 
conditioned media. Mean ± SD of 5 independent experiments. (D, reducing 
STAT3 levels enhances sensitivity to imatinib when K562 cells are cultured in 
conditioned media. Apoptosis of K562 cells cultured in regular media or 
conditioned media, treated with either STAT3 siRNA or control siRNA, in the 
presence or absence of 250 nmol/L imatinib was done using the Annexin V 
detection of apoptotic cells and fluorescence-activated cell sorting analysis. % 
Specific apoptosis was calculated by subtracting background cell death from 
imatinib-mediated cell death. (E), Geometric mean of the 5 combined 
independent experiments showing the 95% confidence intervals and the 
corresponding P-values. The geometric mean was calculated as the 5th root of 
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the product of all the members of the data set in all 5 experiments. The formula is 
depicted as follows: , where ‘a’ represents the data of 
each experiments (1-5). We decided a priori that a p-value <0.05 is statistically 
significant. Representative figure in triplicates (n = 5 independent experiments). 
Addition of GM-CSF, IL-6 and VEGF to Regular Media Induces the Imatinib-
Resistant Phenotype Associated with Conditioned Media 
Previous studies highlighted the involvement of multiple cytokines in 
mediating drug-resistance in CML cells and demonstrate the involvement of more 
than one cytokine in stroma-mediated protection of leukemic cells [171]. 
Therefore, we decided to investigate the role of key cytokines, GM-CSF, IL-6 and 
VEGF, on our conditioned media-induced imatinib-resistant phenotype within our 
model system. We wanted to determine whether the addition of these STAT3-
activating cytokines to regular media induce imatinib-resistance in K562 CML 
cells. To answer this question we cultured K562 cells for 3 hours in regular media 
containing varying concentrations of GM-CSF (0.125 - 2.0 ng/mL), IL-6 (0.25 – 
4.0 ng/mL) or VEGF (3.0 – 48.0 ng/mL), treated the cells with vehicle control or 
500 nmol/L imatinib for 48 hours and analyzed our results via Annexin V 
apoptosis assay followed by FACS analysis.  
Our preliminary results indicate that the addition of these cytokines to 
regular media induced the imatinib-resistant phenotype that has been observed 
in K562 CML cells cultured in conditioned media. Figures 29A and B show that 
2.0 ng/mL GM-CSF and 4.0 ng/mL IL-6, respectively, induced the conditioned 
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media- associated imatinib-resistant phenotype to K562 cells cultured in regular 
media. At 48.0 ng/mL VEGF partially restores this phenotype to K562 cells 
cultured in regular media (Figure 28C). Together, these results suggest that 
multiple cytokines, including GM-CSF, IL-6 and VEGF, may be involved in 
mediating imatinib resistance to CML cells within the context of the bone marrow 
stroma. 
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Figure 29: The Effects of GM-CSF-, IL-6-, or VEGF-Supplemented Regular 
Media on Imatinib-Sensitivity in K562 CML Cells. K562 CML cells were 
cultured for 3 hours in regular media supplemented with varying concentrations 
of GM-CSF, IL-6 and VEGF as indicated added.  After treatment with DMSO 
vehicle control or 500 nmol/L imatinib, cells were allowed to incubate 48 hours at 
37°C, 5% CO2. Cell death was measure using AnnexinV apoptosis assay and 
data was analyzed using FACS. Representative figure (n = 2 independent 
experiments). 
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CHAPTER X 
DISCUSSION AND FUTURE DIRECTION 
 
Over 40 years ago ground-breaking research led to the identification of the 
BCR-ABL chimeric oncoprotein as the initial transforming event in chronic 
myeloid leukemia (CML). This discovery revolutionized the treatment of CML and 
made BCR-ABL an ideal target for drug development. This gave rise to rationally 
designed, small molecule signal transduction inhibitors (STI) specific for the 
tyrosine kinase domain of BCR-ABL, whose constitutive activation is the hallmark 
of BCR-ABL-mediated cell transformation.  
The novel BCR-ABL tyrosine kinase (TK) inhibitor, imatinib mesylate 
(imatinib; IM), represents the first molecularly targeted therapy in patient care 
and has become the gold standard in the treatment for CML patients. By working 
as an ATP-mimic that selectively competes for and binds to the TK domain of 
BCR-ABL, imatinib essentially stabilizes the oncoprotein in an inactive 
conformation that inhibits its enzymatic and transforming activities. The 
remarkable efficacy of this targeted-therapy approach to CML treatment is 
evidenced by the fact that imatinib produces a complete hematological response 
rate, which described the amount of normal leukocyte count in the peripheral 
blood, of 95% in newly diagnosed patients. Furthermore, it produces complete 
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cytogenetic response, which is the absence of detectable Ph-positive cells from 
more than 20 bone marrow cells in metaphase, in 90% of patients with minimal 
toxicity. 
However, despite imatinib’s efficacy and the efficacy of more potent BCR-
ABL inhibitors such as nilotinib and dasatinib, the emergence drug-resistant CML 
challenges us to re-visit our understanding of the mechanisms involved in CML 
disease occurrence, progression and drug-resistance. Clinical data arising from 
studies targeting BCR-ABL inhibitors indicate that although BCR-ABL inhibitors 
are very effective, targeted therapy using a single agent does not eliminate 
minimal residual disease (MRD). This is due to the observation that BCR-ABL-
positive clones are still detectable by quantitative real time-PCR in patients 
undergoing treatment with these inhibitors. Furthermore, these findings are 
consistent with clinical data indicating that patients that discontinue imatinib 
therapy rapidly relapse to a tumor burden which is as great or greater then before 
treatment, suggesting that imatinib does not induce cell death in the stem cell 
population or the population capable of self-renewal [172, 173]. 
Imatinib was specifically designed to bind to and block the ATP-binding 
pocket of the BCR-ABL kinase domain while in an inactive conformation. 
Mutations within the kinase domain disrupt that conformation and thwart the 
ability of imatinib to bind. Therefore, the predominant and most characterized 
mechanism of imatinib-resistance is the emergence of clones possessing point 
mutations within the kinase domain of BCR-ABL. These observations led to the 
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development of second generation BCR-ABL inhibitors, nilotinib and dasatinib, 
which are 30 and 300 times more potent than imatinib, respectively. However, 
despite the efficacy of these inhibitors, their use has not remedied the problem of 
all chemo-resistant CML associated with kinase mutations. Some patients 
present with indomitable pre-existing mutations, such as T315I, which these 
inhibitors cannot eradicate, while other patients acquire this mutation and the 
resistant phenotype during the course of treatment with these inhibitors. 
Furthermore, recent evidence reveals that mutations of the BCR-ABL kinase 
domain occur in approximately 40% to 60% of imatinib-resistant patients [174]. 
Therefore, approximately 50% of these imatinib-resistant CML patients do not 
have kinase domain mutations but are resistant to imatinib by alternative means. 
This suggests that BCR-ABL-independent mechanisms could contribute to 
imatinib-resistance and underscore the need to identify and target BCR-ABL-
independent pathways.  
Models used to investigate the mechanisms of drug resistance seen in 
CML often highlight the cell-autonomous modes of resistance: mutations within 
the tyrosine kinase domain of BCR-ABL itself that either block imatinib binding or 
impair the ability of the kinase to assume the correct conformation required for 
imatinib to bind. But these models often fail to consider the role of the 
surrounding cells and tissues, the “microenvironment”, on the cancer itself and 
the role of this microenvironment on the emergence of the tumor drug-resistance 
phenotype. However, recent studies have draw attention to the involvement of 
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the tumor microenvironment in providing cancer cells an escape from 
chemotherapy-induced cell death. While studying drug resistance in Ph-positive 
acute lymphoblastic leukemia (ALL), William et al. reported on a non-
autonomous mechanism of drug resistance involving cytokine signaling within the 
hematopoietic microenvironment [139]. This study revealed that the contribution 
of BCR-ABL-independent mechanisms was capable of protecting CML cells from 
imatinib-induced cell death. Therefore, the use of an in vitro non-autonomous 
model of drug resistance may provide further insights into the role of host-derived 
stimuli on CML cells in conferring resistance to BCR-ABL inhibitors and may 
provide a greater comprehension of how to combat this mechanism of 
resistance. 
To investigate the role of the bone marrow microenvironment on 
resistance to BCR-ABL inhibitors, we utilized an in vitro bone marrow stromal 
model that exposes CML cells to multiple soluble factors produced by bone 
marrow stroma cells. The human bone marrow stromal cell line, HS-5, served as 
the model of the bone marrow microenvironment as it closely approximates the 
bone marrow-associated cytoprotection observed in drug-treated leukemia 
patients. HS-5 is fibroblastic and has been shown to secrete numerous cytokines 
that are capable of supporting the ex vivo expansion of mature and immature 
hematopoietic cells and their progenitors ([175]. Two hematopoietic CML cell 
lines were used to model the disease: K562 cells originated in the bone marrow, 
are highly undifferentiated and were derived from the pleural effusion of a CML 
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patient in blast crisis phase; KU812 cells are pre-basophilic and originated from 
the peripheral blood of a blast-crisis-phase CML patient.  
Previous work done in our laboratory revealed that adhesion of K562 CML 
cells to fibronectin could provide cell adhesion mediated-drug resistance (CAM-
DR) against imatinib-induced cell death through anti-apoptotic integrin-mediated 
signaling [135]. Similarly, our initial set of experiments using a co-culture 
transwell model system revealed that direct adhesion of K562 cells to HS-5 
stoma cells conferred protection against cell death induced by imatinib, possibly 
through a similar mechanism. Interestingly, however, was the observation that 
HS-5-derived soluble factors were also capable of modulating imatinib response 
in CML cells and confer resistance. This data indicates that both direct contact 
with the bone marrow stroma and soluble factors produced by supporting stroma 
cells play a role in the emergence of the CML drug-resistant phenotype. This 
data also lends support to previous observations that, in addition to targeted 
therapy against BCR-ABL, the tumor-microenvironmental interactions may play a 
crucial role in protecting CML cells from the anti-apoptotic and anti-proliferative 
effects of imatinib. To delineate the contributions of bone marrow stroma-derived 
soluble factors on resistance to BCR-ABL inhibitors and to simplify our model the 
data presented in this dissertation were obtained from the use of HS-5-derived 
conditioned media. 
It has been demonstrated here that imatinib induces a high rate of cell 
death in CML cells cultured in regular media (RM: RPMI + 10% fetal bovine 
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serum). However, using the same media conditioned for three hours by the HS-5 
human stroma cells (CM) is sufficient to cause resistance to imatinib-induced cell 
death in K562 and KU182 CML cells. Since HS-5 stromal cells produce cytokines 
that support the growth and differentiation of HSCs, this data suggests that HS-5-
derived soluble factor(s) may be involved in mediating this imatinib-resistant 
phenotype in CML cells. Furthermore, HS-5 conditioned media could be stored at 
-80°C and retain its ability to produce imatinib resistance in these CMLS cells, 
while heat-inactivated conditioned media lost this ability. These data indicate that 
the soluble factor(s) conferring resistance to imatinib is quite stable and capable 
of preserving its function during the freezing and thawing process. Additionally, 
heat-inactivation of conditioned media would destroy its protein components, 
which includes growth factors and cytokines. The observation that heat-
inactivated conditioned media restores imatinib-sensitivity to CML cells 
demonstrates that the protective component in conditioned media is a protein. 
Based on findings of similar studies, the hematopoietic cytokine granulocyte 
macrophage-colony stimulating factor (GM-CSF) and interleukin 6 (IL-6) are two 
potential cytokines that may be involved in mediating the BCR-ABL-independent 
imatinib-resistant phenotype seen in our model. 
While HS-5-derived conditioned media increased the clonogenic survival 
of K562 cells, exposure of CML cells to the soluble factors in conditioned media 
did not lead to an increase in cell proliferation. This indicates that the soluble 
factor(s) mediate imatinib-resistance through cell survival pathways. There are 
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several well-characterized cytokine-receptor-activated cell survival pathways that 
may be involved in promoting clonogenic survival of these cells. The Janus 
activated kinase (JAK)/STAT signal transduction pathway is important in 
converting cytokine-receptor signals into downstream survival signals and is 
often constitutively activated in hematopoietic malignancies. Studies show that in 
BCR-ABL-expressing cells, constitutive activation of JAKs is associated with 
constitutive STAT3 Try-705 phosphorylation. Studies show that STAT5 is also 
constitutively activated in CML cells. Other survival pathways that may enhance 
the clonogenic survival of CML cells are the anti-apoptotic phosphatidylinositol 3-
kinase (PI3K)/AKT signaling pathway, whose activation has been shown to not 
only be involved in BCR-ABL-mediated cell transformation but also resistance to 
BCR-ABL inhibitors. Additionally, BCR-ABL also signals through the extracellular 
signal regulated kinase 1/2 (ERK-1/2) pathway and has been implicated in the 
anti-apoptotic activities of BCR-ABL. 
Data presented here revealed that when CML cells were no longer 
exposed to the protective soluble factor(s) associated with HS-5 conditioned 
media and were re-cultured in regular media, the imatinib-resistant phenotype 
diminished. This demonstrates that withdrawal of CML cells from bone marrow 
stroma-secreted soluble factor(s) was sufficient to re-sensitize these cells to the 
apoptotic effects of imatinib. It is possible that this observation is attributable to 
the termination of cytokine-receptor-mediated signaling. Furthermore, this data 
reveals a direct correlation between the presence of HS-5-derived soluble factors 
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and the emergence of imatinib resistance, an observation that has also been 
highlighted in other studies.  
The hypothesis within this dissertation is based on the importance of 
soluble factors specific to the bone marrow microenvironment in promoting 
chemoresistance in CML cells. To accurately test this hypothesis it was important 
to investigate whether K562 CML cells could condition its own media via 
autocrine secretion of its own soluble factors and induce chemoresistance. 
Additionally, we investigated whether other non-stromal cell lines were capable of 
conveying protection against cell death induced by imatinib. In either case, if 
there is protection against cell death induced by BCR-ABL inhibitors then this 
would demonstrate that the bone marrow microenvironment may not be 
responsible for providing chemo-resistance to CML cells and would discredit its 
role in modulating drug response within our model. Conditioned media from K562 
CML cells and two hematopoietic cell lines, U937 and 8226, were generated in 
the same manner as HS-5-derived conditioned media: these cells were cultured 
in regular media for 3 hours, enabling the media to become conditioned by the 
different cell lines; the conditioned media was then collected by centrifugation to 
remove debris and utilized in subsequent experiments. K562 CML cells were 
cultured in regular media and several types of conditioned media, as previously 
described. The cells were treated with imatinib for 48 hours to induce cell death, 
which was measured using the Annexin V apoptosis assay.  Our data revealed 
that of the different conditioned media generated, only HS-5-derived conditioned 
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media was capable of conveying imatinib-resistance in K562 CML cells. This 
data validated the unique role and importance of soluble factors specific to the 
bone marrow stroma in protecting CML cells from death induced by imatinib.   
There are numerous bone marrow stroma-derived soluble factors and 
cytokines involved in the growth and differentiation hematopoietic cells that may 
also be crucial in conferring resistance to BCR-ABL inhibitors. According to 
Torok-Storb (1999), the human HS-5 stroma cell produces a cocktail of cytokines 
that include IL-6, GM-CSF, G-CSF and VEGF. It is conceivable that these 
cytokines could confer protection against imatinib-induced cell death to varying 
degrees either individually on in combination with each other. In fact, while 
studies by Wang et al. focused on the role of the autocrine secretion of GM-CSF 
in mediating resistance to BCR-ABL inhibitors in CML cells [140], Weisberg et al. 
emphasized the involvement of the bone marrow stroma as a whole in mediating 
protection against CML cell death by using a cocktail of stroma-derived cytokines 
[171]. 
Our data from the bone marrow stromal model lends credence to the 
involvement of survival signaling mediated by stroma-derived soluble factors in 
the emergence of chemo-resistant CML. This is also evidenced by our 
observations that neither nilotinib nor dasatinib are capable of overriding the 
protective effects of HS-5-secreted soluble factors on K562 CML cells. This 
demonstrates that even though one inhibitor was designed to bind more 
stringently to the tyrosine kinase domain of BCR-ABL and the other was 
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designed to recognize and bind to both its active and inactive conformations, the 
development and use of these more potent, rationally-designed inhibitors was not 
sufficient to address this mechanism of resistance involving the bone marrow 
microenvironment. There is growing interest in research to target components of 
the hematopoietic tumor microenvironment as a way to enhance the efficacy of 
targeted therapy against CML. While research that addresses BCR-ABL-
independent mechanisms of imatinib resistance have gained momentum, there 
are also concerns about the effects that targeting the bone marrow 
microenvironment may have on normal hematopoiesis and surrounding cells. 
Studies suggest that the best initial approach is to target individual signal 
transduction pathways that are constitutively activated in malignant 
hematopoietic cells. 
BCR-ABL’s modular domains make it capable of activating several signal 
transduction pathways that can contribute to enhanced CML cell survival, 
including Ras/ERK, PI3K/AKT, and STAT5 signal transduction pathways. These 
pathways can also be activated by external signals including growth factors, 
cytokines, and interactions with extracellular matrices. Furthermore, studies 
suggest that these pathways can be reconstituted in a BCR-ABL-independent 
manner by these external signals. Our data supports this observation and reveals 
that HS-5-derived soluble factors are capable of BCR-ABL-independent 
constitutive STAT3 activation via Tyr-705 phosphorylation. Studies show that 
constitutive STAT3 Tyr-705 phosphorylation and activation is mediated by 
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activated JAKs. Activated STAT3 homo- or heterodimerizes and translocates to 
the nucleus where it leads to the transcriptional activation of STAT3 target anti-
apoptotic genes.  
Studies show that cytokines that are capable of STAT3 activation include 
IL-6, vascular endothelial growth factor (VEGF), and GM-CSF. Here we 
demonstrate that not only does the exposure of either K562 or KU812 CML cells 
to conditioned media derived from HS-5 cells resulted in the rapid and sustained 
increase in phospho-Y705 STAT3 levels, but we also show that this exposure to 
HS-5-derived soluble factors also led to an increase in the protein expression 
levels of STAT3 downstream targets, Bcl-xL, Mcl-1 and survivin. This suggests 
that HS-5-derived soluble factors may be involved in the activation of STAT3, 
which in turn resulted in STAT3-mediated expression of these anti-apoptotic 
proteins. Furthermore, the addition of imatinib does not reduce phospho-Y705 
STAT3 levels or the levels of its downstream targets. This demonstrates that 
activation of STAT3 is indeed independent of BCR-ABL activity and highlights the 
importance of BCR-ABL-independent mechanisms in facilitating the imatinib-
resistant phenotype. This data also contradicts an earlier observation made by 
Coppo et. al. which showed that the constitutive phosphorylation of STAT3 on 
Tyr-705 was dependent on BCR–ABL [168]. This difference may be attributable 
to the fact that they utilized a hematopoietic cell line that was retrovirally 
transduced with a p210-BCR-ABL expressing vector as oppose to utilizing a cell 
line obtained from CML patients. 
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Since studies show that STAT3 activation can also be accomplished 
through the activities of SRC family kinases (SFKs), it was important to 
determine whether the increase in BCR-ABL-independent STAT3 activity was 
attributable to SFKs. Our data showed that when K562 CML cells were treated 
with the dual BCR-ABL/SFK inhibitor, dasatinib, sustained phosphorylation of 
STAT3 was still observed in those cells cultured in HS-5-derived conditioned 
media, while phospho-SRC levels were attenuated. This observation eliminates 
the involvement of SFKs in the increased activation of STAT3 that we observed 
in our model and lends greater support to the involvement of HS-5 derived 
soluble factors in mediating STAT3 activation, possible through cytokine 
receptor-engagement and JAKs activation. While investigating the role of STAT3 
activation in K562 CML cells exposed to HS-5 soluble factors and assessing the 
mechanism(s) involved in its activation, one interesting and consistent 
observation was that the use of increasing concentrations of imatinib resulted in 
increased STAT3 activation. In examining this further, other studies have 
reported that BCR-ABL can activate STAT5 and STAT1 independently of the 
activation of JAKs [154]. Furthermore, a dominant-negative STAT5 was shown to 
inhibit colony formation of K562 cells and blocking BCR-ABL was shown to inhibit 
STAT5-dependent DNA binding as well as STAT5 target genes, Bcl-xL and Mcl-1 
[169, 176-180]. Bcl-xl, Mcl-1, and cyclin D1 represent genes that can be 
regulated by either STAT5 or STAT3 activation. Therefore, based on these 
observations, we propose that within the bone marrow microenvironment STAT3 
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can compensate for BCR-ABL-dependent activation of STAT5-dependent genes, 
which are critical for CML cell survival, when STAT5 activity is blocked by BCR-
ABL inhibitors. In support of this hypothesis, our data also indicate that when 
K562 cells were treated with imatinib, the levels of Bcl-xL, survivin, and Mcl-1 
were increased when cells were cultured in conditioned media compared with 
cells cultured in regular media. Together, these data suggest that, depending on 
culture conditions, K562 CML cells may have plasticity with respect to STAT-
dependency.  
To determine the causal role of STAT3 activation in our drug-resistant 
phenotype associated with conditioned media, we reduced STAT3 levels using 
siRNA technology. Here we show that this reduction in STAT3 levels led to the 
enhanced sensitivity of K562 CML cells to imatinib-induced cell death. 
Importantly, this increased imatinib-sensitivity in CML cells was observed only 
within the context of the bone marrow stroma model, as reducing STAT3 levels in 
regular media did not result in increased cell death. These data highlight the 
contribution and significance of BCR-ABL-independent STAT3 activation in 
reconstituting BCR-ABL-mediated survival signaling events that promote CML 
progression. Furthermore, our data indicate that while the initial BCR-ABL insult 
that initiated the disease within the primitive hematopoietic stem cell population is 
crucial to CML pathogenesis, clearly soluble factors unique to the hematopoietic 
microenvironment are capable of protecting CML cells from the apoptotic effects 
of BCR-ABL inhibitors. To address the question recently posed by Charles 
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Sawyers in his news brief entitled ‘Where lies the blame for resistance - tumor or 
host?’ [181], the synthesis of data presented here, along with data presented in 
previous studies, suggest that both the tumor and the host are responsible. 
Consequently, the use of BCR-ABL inhibitors alone is not sufficient to address 
this type of resistance, which is associated with BCR-ABL-independent STAT3 
activation. While BCR-ABL inhibitors target the fusion oncoprotein, it does not 
target STAT3. Therefore, these data also provide pre-clinical rationale for 
targeting STAT3 in order to increase the efficacy of BCR-ABL inhibitors in 
treating drug-resistant CML cells. To that end, a multi-targeted approach to CML 
patient care that involves the combined use of BCR-ABL inhibitors and STAT3 
inhibitors may prove more effective in addressing this type of drug-resistant CML. 
In vitro studies to identify compounds that are highly selective for STAT3 have 
highlighted the effectiveness of cisplatin/IS3 295 [182] as well as cucurbitacin Q 
[183] in inhibiting STAT3 activation. 
Bone marrow stroma-derived conditioned media consists of a complex 
mixture of cytokines and other soluble factors that can be source of survival 
signals affecting cell differentiation, expansion and survival. The functional 
redundancy of many of these soluble factors and their signaling receptors may 
converge to activate STAT3 and circumvent cell death induced by BCR-ABL 
inhibitors. Since several studies have highlighted the involvement of GM-CSF, IL-
6 and VEGF in the emergence and progression of hematological malignancies, 
we examined the contribution of these cytokines in our drug-resistant phenotype. 
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We wanted to determine whether exposure of CML cells to these cytokines can 
modulate their response BCR-ABL inhibitors. Here, our data revealed that when 
these cytokines were added to regular media in varying concentrations a dose-
dependent imatinib resistant phenotype emerged. This is evidenced by the 
steady reduction in imatinib-induced CML cell deaths, which correlated with 
increased cytokine concentrations. The addition of 2.0 ng/mL of GM-CSF, 4.0 
ng/mL of IL-6 or 48.0 ng/mL of VEGF to regular media initiated the return of the 
imatinib-resistant phenotype associated with HS-5 conditioned media. These 
results, which are consistent with observations made in similar studies, indicate 
that these cytokines may be working individually or cooperatively to protect CML 
cells from death induced by BCR-ABL inhibitors.  
Furthermore, data from other studies revealed that conditioned media 
from malignant cell lines expressing high levels of phospho-STAT3 also 
contained cytokines that are capable of stimulating STAT3 activation, such as IL-
6. To determine the involvement of cytokines such as IL-6, GM-CSF and VEGF 
within our model, their activity in conditioned media could also be impeded using 
blocking antibodies. For example, IL-6 signal transduction, which activates 
STAT3 through the glycoprotein (gp) 130/JAK pathway and is notable for its 
pleiotropic tumor-promoting activities, could be blocked using a gp130-blocking 
antibody or an IL-6-blocking antibody (such as BR-3 and 522, respectively; 
provided by Cell Sciences, Inc.). Alternatively, to validate the results obtained 
from the use of cytokine-blocking antibodies, the gene expression of these 
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cytokines in HS-5 cells could also be sequentially silenced using siRNA 
technology. 
To identify the specific soluble factor(s) causative for imatinib resistance 
and STAT3 activation within our model, one global approach is to utilize 
multiplexed bead-based assays that efficiently detect and quantify several 
cytokines simultaneously (Invitrogen). These assays consist of capture-
antibodies conjugated to biologically inert beads and are designed to identify 
various soluble factors, including cytokines, with enhanced speed and accuracy. 
Furthermore, since our data revealed that HS-5 cells do not require serum to 
produce the protective soluble factors, we could identify the active soluble 
factor(s) in HS-5 conditioned media that confers imatinib resistance by 
fractionating the SF-CM into its protein components and performing the Annexin 
V apoptosis assay on each fraction. Fractionation could be accomplished in 
several ways. Centricon spin columns (Miliipore) can separate the components of 
conditioned media by molecular weight. Additionally, fractionation can also be 
accomplished using liquid chromatography or mass spectrometry. 
Constitutive STAT3 activation is associated with several human 
malignancies, including solid tumors and hematological diseases. Interestingly, 
we observed that reducing STAT3 levels sensitized imatinib-resistant CML cells 
to its apoptotic effects. It is possible that while BCR-ABL-mediated oncogenic 
signaling events are being impeded by imatinib, the non-autonomous activation 
of STAT3 by soluble factors within the bone marrow microenvironment facilitates 
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these signal transduction events (see Figure 30 for proposed model). 
Additionally, our data provides preclinical rationale to support the use of STAT3 
inhibitors as BCR-ABL-inhibitor sensitizers and for conduction validating our 
observations in studies using primary patient specimens. One set of experiments 
would be to confirm data presented in other studies that show increased STAT3 
activation in primary CML patient samples when compared to healthy bone 
marrow donors. Furthermore, cells from CML patient can be used to delineate 
whether small molecule inhibitors targeting STAT3, such as phosphotyrosyl 
peptides [184], are capable of enhancing the efficacy of BCR-ABL inhibitors 
using in vivo models. 
Furthermore, patient’s samples could be used to examine whether STAT3 
activation enables CML cells to escape complement-dependent cytotoxicity via 
CD46 expression. It has been reported that STAT3 activation is capable of 
inducing the expression of CD46, one of the complement-regulatory proteins 
(CRPs) expressed on the surface of normal and transformed cells. While 
complement proteins target bacteria and cancerous cells for lysis [185], cancer 
cells often escape elimination by complement proteins. This escape mechanism 
is due in part to the expression of this membrane-bound CRP, which inactivates 
complement components. It would be of interest to e whether increased STAT3 
activation in patient samples also resulted in this escape mechanism. 
Studies show that BCR-ABL-positive MRD in some imatinib-resistant CML 
cells are characterized by increased activation of the PI3K/AKT and Ras/MEK 
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signal transduction pathways. These pathways are capable of mediating cell 
survival by transmitting signals from multiple cell surface receptors to 
transcription factors within the nucleus. However, the mechanisms responsible 
for the enhanced activation of these survival pathways remain poorly understood. 
Future studies may include investigating whether the PI3K/AKT and Ras/MEK 
signal transduction remains activated in imatinib-treated CML cells cultured in 
conditioned media. Furthermore, a SCID-hu in vivo model could be implemented 
to validate the involvement of these pathways in modulating imatinib response in 
CML cells.  
In conclusion, while imatinib and other BCR-ABL inhibitors are highly 
effective in treating CML patients and addressing mechanisms of acquired 
resistance, the high rates of patient relapse and the persistence of MRD CML 
challenges us to continuously expand our understanding of CML pathogenesis 
and seek innovative solutions to combat this disease. Data presented here 
demonstrate that targeted therapy using a single agent does not eradicate drug 
resistance associated with the bone marrow microenvironment. However, the 
use of combinational therapy that targets BCR-ABL as well as stroma-derived 
soluble factors promises to increase the efficacy of BCR-ABL inhibitors by 
sensitizing cells to their apoptotic effects. This accomplishment would translate 
into increased remission rates among CML patients and further revolutionize 
oncology therapeutics. Additionally, these data demonstrate the importance of 
bone marrow stroma models that consider the tumor microenvironment in 
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identifying novel targets that enhance the efficiency of existing targeted drug 
therapies.  
 
Figure 30: Proposed Mechanisms of Resistance to BCR-ABL Inhibitors in 
Chronic Myeloid Leukemia Cells. Data from our bone marrow stroma model 
show increased and sustained STAT3 activation in CML cells. Bone marrow 
stroma cells secrete numerous soluble factors that are capable of STAT3 
activation. Additionally, soluble factors within the bone marrow microenvironment 
may be capable of reconstituting BCR-ABL downstream signaling events, such 
as the Ras/MEK and PI3K/AKT cell survival signal transduction pathways. 
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